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Abstract
T2DM is linked to an increase in the fracture rate as compared to the nondiabetic population even with normal or raised Bone Mineral Density (BMD).
Previous studies have addressed the question of how T2DM induces osteoporosis; the
exact underlying mechanism is still elusive. Bones undergo continuous remodeling
throughout life. Bone remodeling implicates the coupling of osteoclastic bone
resorption and osteoblastic bone formation. This process is controlled by numerous
genetic, hormonal, and neurogenic mechanisms. Osteoporosis is a result of bone loss
that occurs by uncoupled remodeling. The existing evidence indicates that short noncoding RNAs known as microRNAs (miRNAs), are the key post-transcriptional
repressors of gene expression, and growing numbers of novel miRNAs have been
verified to play vital roles in the regulation of osteogenesis, osteoclastogenesis, and
adipogenesis, revealing how they interact with signaling molecules to control these
processes. This study aims to identify the changes in miRNAs levels related to the
bone remodeling cycle in bones of type 2 diabetic rats. Three-month-old female Wistar
rats (n=24) were obtained from the animal house facility at United Arab Emirates
University for this study. All animal procedures were approved by the animal ethical
committee at United Arab Emirates University (ERA_2017_5597). Animals (n=12)
were fed with a high-calorie diet (D12492 diet; Research Diets, Inc, USA) for 3 weeks
followed by injection of two lower doses of STZ (30 mg/kg intraperitoneally) which
was administered at weekly intervals. Rats having blood glucose >15 mmol/liter were
considered as diabetic and were used for this study. The animals were sacrificed after
8, 10, and 14 weeks of the onset of diabetes. The tibia was dissected out and used for
the extraction of miRNAs using the mirVana™miRNA isolation kit provided by
Ambion (AM 1560). miRNAs known to be related to bone metabolism were assayed
by quantitative RT-PCR using Taqman probes and primers (4427975, Thermofisher
Scientific) in the serum and bone tissue samples. This study revealed that in 8 weeks
of the duration of T2DM, the dysregulation of miR-20a, miR-21, miR-29a, miR-31,
and miR-155 affects the bone remodeling cycle by promoting osteoclastogenesis and
suppressing osteoblast differentiation. In 10 weeks of the duration of T2DM, the
dysregulation of miR-20a, miR-21, miR-29a, miR-31, and miR-155 affects the bone
remodeling cycle by suppressing osteoclastogenesis, and suppressing bone formation.

viii
In 14 weeks of the duration of T2DM, the dysregulation of miR-20a, miR-21, miR29a, miR-31, and miR-155 affects the bone remodeling cycle by suppressing both
osteoclastogenesis and osteoblast differentiation. Moreover, miR-21 and miR-155
could be used as potential serum biomarkers.
The study concludes that the longer duration of T2DM adversely affects the
bone, indicating an increased bone fragility. The research project resulted in a novel
and innovative perspective in defining the mechanism of osteoporosis in type 2
diabetes mellitus through miRNAs with the potential to be used as diagnostic
biomarkers to assess fracture risk or therapeutic targets for type 2 diabetic osteopathy.
Keywords: Type 2 diabetes mellitus, osteoporosis, bone remodeling cycle,
microRNAs.
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)Title and Abstract (in Arabic

تحديد المايكرو آر إنات ) (microRNAsالمرتبطة بأمراض العظام في مرض السكري
النوع الثاني
الملخص

ﻣﺮﺽ ﺍﻟﺴﻜﺮﻱ ﺍﻟﻨﻮﻉ ﺍﻟﺜﺎﻧﻲ ﻣﺮﺗﺒﻂ ﺑﻌﻠﻮ ﻓﻲ ﻧﺴﺒﺔ ﺍﻟﻜﺴﻮﺭ ﻣﻘﺎﺭﻧﺔ ﺑﺎﻟﺴﻜﺎﻥ ﺍﻟﺬﻳﻦ ﻻ ﻳﻌﺎﻧﻮﻥ
ﻣﻦ ﻣﺮﺽ ﺍﻟﺴﻜﺮﻱ ﺣﺘﻰ ﻣﻊ ﻛﺜﺎﻓﺔ ﻁﺒﻴﻌﻴﺔ ﺃﻭ ﻋﺎﻟﻴﺔ ﻓﻲ ﻣﻌﺎﺩﻥ ﺍﻟﻌﻈﺎﻡ .ﺍﻟﺪﺭﺍﺳﺍﺕ ﺍﻟﺴﺎﺑﻘﺔ ﺗﻄﺮﻗﺖ
ﺇﻟﻰ ﺍﻟﺴﺆﺍﻝ ﻓﻲ ﻛﻴﻒ ﻟﻤﺮﺽ ﺍﻟﺴﻜﺮﻱ ﺍﻟﻨﻮﻉ ﺍﻟﺜﺎﻧﻲ ﺃﻥ ﻳﺴﺒﺐ ﻡﺮﺽ ﻫﺸﺍﺸﺔ ﺍﻟﻌﻈﺍﻡ؛ ﺍﻵﻟﻴﺔ ﺍﻷﺳﺎﺳﻴﺔ
ﺍﻟﺪﻗﻴﻘﺔ ﻟﻬﺬﺍ ﺍﻟﺸﻲء .ﻻﻻﺍﻝ ﻣﺒﻬﻣﺔ .ﺗﺨﻀﻊ ﺍﻟﻌﻈﺎﻡ ﻟﻌﻤﻞﻴﺔ ﺇﻋﺎﺩﺓ ﺘﺸﻜﻴﻞ ﻣﺴﺘﻤﺮﺓ ﻁﻮﺍﻝ ﺍﻟﺤﻴﺎﺓ .ﺗﻨﻄﻮﻱ
ﻋﻤﻠﻴﺔ ﺇﻋﺎﺩﺓ ﺗﺸ ﻜﻴﻟ ﺍﻟﻌﻈﺍﻡ ﻋﻠﻰ ﺍﻗﺘﺮﺍﻥ ﻋﻤﻠﻴﺔ ﺍﻣﺘﺼﺎﺹ ﺍﻟﻌﻈﻢ ﻭ ﺗﻜﻮﻳﻦ ﺍﻟﻌﻈﻢ .ﻳﺘﻢ ﺍﻟﺘﺤﻜﻢ ﻓﻲ ﻫﺬﻩ
ﺍﻟﻌﻤﻠﻴﺔ ﻣﻦ ﺧﻼﻝ ﺍﻟﻌﺪﻳﺪ ﻣﻦ ﺍﻵﻟﻴﺎﺕ ﺍﻟﺠﻴﻨﻴﺔ ﻭ ﺍﻟﻬﺮﻣﻮﻧﻴﺔ ﻭ ﺍﻟﻌﺼﺒﻴﺔ .ﻣﺮﺽ ﻫﺸﺍﺸﺔ ﺍﻟﻌﻈﺍﻡ ﻫﻲ
ﻧﺘﺎﺝ ﻟﻔﻘﺪ ﺍﻟﻌﻈﺍﻡ ﺍﻟﺬﻱ ﻳﺤﺪﺙ ﻣﻦ ﺧﻼﻝ ﻋﻤﻠﻴﺔ ﺇﻋﺎﺩﺓ ﺗﺸﻜﻴﻟ ﺍﻟﻌﻈﺍﻡ ﺍﻟﻐﻴﺮ ﻣﻘﺘﺮﻧﺔ.ﻷﻷﻱﻷ ﺍﻷﺩﻟﺔ
ﺍﻟﻤﻮﺟﻮﺩﺓ ﺇﻟﻰ ﺃﻥ ﺍﻷﻷﻷﺍﺽ ﺍﻟﻨﻮﻭﻳﺔ ﺍﻟﺮﺍﻳﺒﻮﺯﻳﺔ ﺍﻟﻘﺼﻳﺮﺔ ﻭ ﺍﻟﻐﻳﺮ ﻤﺸﻓﺮﺔ ﺍﻟﻤﻌﺮﻭﻓﺔ ﺑﺍﺳﻢ ﺍﻟﻤﺍﻳﻜﺮﻭ
ﺁﺭ ﺇﻧﺎﺕ ) ،(microRNAsﻫﻲ ﺍﻟﻤﺜﺒﻄﺎﺕ ﺍﻟﺮﺋﻴﺴﻴﺔ ﻟﻟﺘﻌﺒﻴﺮ ﺍﻟﺠﻴﻨﻲ ﺑﻌﺪ ﻋﻤﻟﻴﺔ ﺍﻟﻨﺴﺦ(post-
) ،transcriptionﻭ ﻗﺪ ﺗﻢ ﺍﻟ ﺘﺤﻘﻘ ﻣﻦ ﺃﻋﺪﺍﺩ ﻣﺘﺰﺍﻳﺪﺓ ﻣﻦ ﺍﻟﻤﺎﻳﻜﺮﻭ ﺁﺭ ﺇﻧﺎﺕ ﺍﻟﺠﺪﻳﺪﺓ ﻟﺘﻠﻌﺐ ﺃﺩﻭﺍﺭﺍ ً
ﺣﻴﻮﻳﺔ ﻓﻲ ﺗﻨﻈﻴﻢ ﺗﻜﻮﻥ ﺧﻼﻳﺎ ﺗﻜﻮﻳﻦ ﺍﻟﻌﻈﻢ ) ،(osteogenesisﺗﻜﻮﻥ ﺧﻼﻳﺎ ﺍﻣﺘﺼﺎﺹ
ﺍﻟﻌﻈﻢ ) ،(osteoclastogenesisﺗﻜﻮﻥ ﺧﻼﻳﺎ ﺗﻜﻮﻳﻦ ﺍﻟﺸﺤﻢ ) ،(adipogenesisﻳﻜﺸﻒ ﻋﻦ ﻛﻴﻔﻴﺔ
ﺗﻔﺎﻋﻠﻬﺎ ﻣﻊ ﺟﺰﻳﺌﺎﺕ ﺍﻹﺷﺎﺭﺓ ) (signaling moleculesﻠﻠﺘﺤﻜﻢ ﻓﻲ ﻫﺬﻩ ﺍﻟﻋ.ﻠﻴﺎﺕ ﺍﻟﺘﻨﻈﻴﻤﻴﺔ.
ﺍﻟﻬﺪﻑ ﻣﻦ ﻫﺬﻩ ﺍﻟﺪﺭﺍﺳﺔ ﻫﻲ ﺗﺤﺪﻳﺪ ﺍﻟﺘﻐﻴﺮﺍﺕ ﻓﻲ ﻤﺴﺘﻮﻳﺎﺕﺍﻟﻤﺍﻲﻜﺭﻭ ﺁﺭ ﺇﻧﺎﺕ ﺍﻟﻤﺘﻌﻟﻘﺔ ﺑﺪﻭﺭﺓ ﺇﻋﺎﺩﺓ
ﺗﺸﻜﻴﻞ ﺍﻟﻌﻈﺎﻡ ﻓﻲ ﻋﻈﺎﻡ ﺍﻟﻔﺌﺮﺍﻥ ﺍﻟﻤﺼﺍﺑﺔ ﺑﻤﺮﺽ ﺍﻟﺴﻜﺮﻱ ﺍﻟﻨﻮﻉ ﺍﻟﺜﺎﻧﻲ .ﺗﻢ ﺍﻟﺤﺼﻮﻝ ﻋﻠﻰ ﺇﻧﺎﺙ
ﻓﺌﺮﺍﻥ ﺍﻟﻮﻳﺴﺗﺎﺭ ) (Wistar ratsﺍﻟﺒﺎﻟﻐﺔ ﻣﻦ ﺍﻟﻌﻤﺮ ﺛﻼﺛﺔ ﺃﺷﻬﺮ )ﺍﻟﻌﺪﺩ= (24ﻣﻦ ﻣﺮﻓﻖ ﺟﺎﻣﻌﺔ
ﺍﻹﻣﺎﺭﺍﺕ ﺍﻟﻌﺮﺑﻴﺔ ﺍﻟﻤﺘﺤﺪﺓ ﻟﻬﺬﻩ ﺍﻟﺪﺭ ﺍ ...ﺗﻤﺖ ﺍﻟﻤﻮﺍﻓﻘﺔ ﻋﻠﻰ ﺟﻤﻴﻊ ﺍﻹﺟﺮﺍءﺍﺕ ﺍﻟﻤﺘﻌﻠﻘﺔ ﺑﺎﻟﺤﻴﻮﺍﻧﺎﺕ
ﻣﻦ

ﻗﺒﻞ

ﺍﻟﻤﺘﺤﺪﺓ

ﻟﺠﻨﺔ

ﺃﺧﻼﻗﻴﺍﺕ

ﺍﻟﺘﻌﺍﻣﻟ

).(ERA_2017_5597

ﺗﻢ

ﻣﻊ

ﺍﻟﺤﻴﻮﺎﻥ

ﺗﻐﺬﻳﺔ

ﺑﺠﺎﻣﻌﺔ

ﺍﻟﺤﻴﻮﺍﻧﺎﺕ

ﺍﻹﻣﺎﺭﺍﺕ

ﺍﻟﻌﺮﺑﻴﺔ

)ﺍﻟﻌﺪﺩ=(12

ﺑﻨﻈﺎﻡ

ﻏﺬﺍﺋﻲ ) (D12492diet; Research Diets, Inc, USAﻋﺎﻟﻲ ﺍﻟﺴﻌﺮﺍﺕ ﺍﻟﺤﺮﺍﺭﻳﺔ ﻟﻤﺪﺓ 3
ﺃﺳﺎﺑﻴﻊ ﻣﺘﺒﻮﻋﺎ ً ﺑﺤﻘﻦ ﺟﺮﻋﺘﻴﻦ ﻣﺨﻔﻀﺘﻴﻦ ﻣﻦ ﺍﻝ (30 mg/kg intraperitoneally) STZﻭ ﺍﻟﺘﻲ
ﺗﻢ ﺇﻋﻄﺎﺅﻫﺎ ﻋﻠﻰ ﻓﺘﺮﺍﺕ ﺃﺳﺒﻮﻋﻴﺔ .ﺍﻋﺘﺒﺮﺕ ﺍﻟﻔﺌﺮﺍﻥ ﺍﻟﺘﻲ ﺗﺤﺘﻮﻱ ﻋﻠﻰ ﻧﺴﺒﺔ ﺍﻟﺴﻜﺮ ﻓﻴ ﺍﻟﺪﻡ ﺃﻛﺜﺮ ﻣﻦ
 15ﻣﻠﻲ ﻣﻮﻝ/ﻟﺘﺮ ﻣﺼﺎﺑﺔ ﺑﻤﺮﺽ ﺍﻟﺴﻜﺮﻱ ﻭ ﺍﺳﺘﺨﺪﻣﺖ ﻓﻲ ﺩﺭﺍﺳﺘﻨﺎ .ﺗﻢ ﺍﻟﺘﻀﺤﻴﺔ ﺑﺎﻟﺤﻴﻮﺍﻧﺎﺕ ﺑﻌﺪ

x

 10 ،8ﻭ  44ﺃﺳﺒﻮﻋﺎ ً ﻣﻦ ﻅﻬﻮﺭ ﻣﺮﺽ ﺍﻟﺴﻜﺮﻱ .ﺗﻢ ﺗﺸﺮﻳﺢ ﻋﻈﻤﺔ ﺍﻟﻈﻨﺒﻮﺏ ) (tibiaﻭ ﺗﻢ
ﺍﺳﺘﺨﻻﺍﻻﻻﺍ ﻻﺳﺘﺨﺮﺍﺝ ﺍﻟﻤﺎﻳﻜﺮﻭ ﺁﺭ ﺇﻧﺎﺕ ﺑﺎﺳﺘﺨﺪﺍﻡ ﻁﻘﻢ ﻋﺰﻝ ﺍﻟﻤﺎﻳﻜﺮﻭ ﺁﺭ ﺇﻧﺎﺕ ﻣﻦ
ﻣﻴﺮﻻﺍﻧﺎ ) (mirVanaﺍﻟﻤﻘﺪﻣﺔ ﻣﻦ ) .Ambion (AM 1560ﺗﻢ ﺗﻘﻴﻴﻢ ﺗﻌﺒﻴﺮ ﺍﻟﻤﺎﻳﻜﺮﻭ ﺁﺭ ﺇﻧﺎﺕ
ﺍﻟﻤﺘﻌﻟﻘﺔ ﻋﻤﻠﻴﺔ ﺍﻷﻳﺾ ﺍﻠﻌﻈﻤﻴﺔ ﺑﻮﺍﺳﻄﺔ ﺗﺤﻠﻴﻠ ﺍﻟﺒﻲ ﺳﻲ ﺁﺭ-ﺍﻟﻮﻗﺖ ﺍﻟﺤﻘﻴﻘﻲ ﺍﻟﻜﻤﻴ (quantitative
) RT-PCRﺑﺎﺴﺘﺨﺪﺍﻡ ﻣﺴﺎﺑﻴﺮ ﻭ ﺑﺎﺩﺋﺎﺕ ﺗﺎﻕ ﻣﺎﻥ ) (Taqman probes and primersﻓﻲ
ﻋﻴﻨﺎﺕ ﺍ ﻟﻤﺼﻟ ﻭ ﺃﻧﺴﺠﺔ ﺍﻟﻌﻈﺎﻡ .ﻧﺘﺞ ﻋﻦ ﻫﺬﺍ ﺍﻟﻤﺸﺮﻭﻉ ﺍﻟﺒﺤﺜﻲ ﻣﻨﻈﻮﺭ ﺟﺪﻳﺪ ﻭ ﻣﺒﺘﻜﺮ ﻓﻲ ﺗﺤﺪﻳﺪ
ﺁﻟﻴﺔ ﻣﺮﺽ ﻫﺸﺎﺸﺔ ﺍﻟﻌﻈﺎﻡ ﻓﻲ ﻣﺮﺽ ﺍﻟﺴﻜﺮﻱ ﺍﻟﻨﻮﻉ ﺍﻟﺜﺍﻼﻳ ﻣﻦ ﺧﻼﻝ ﺍﻟﻤﺍﻳﻜﺮﻭ ﺁﺭ ﺇﻧﺎﺕ ﻣﻊ ﺇﻣﻜﺎﻧﻴﺔ
ﺍﺳﺘﺨﺪﺍﻤﻬﺍ ﻛﻤﺆﺷﺮﺍﺕ ﺑﻴﻮﻟﻮﺟﻴﺔ ﺗﺸﺨﻴﺼﻴﺔ ﻟﺘﻘﻴﻴﻢ ﻣﺨﺎﻁﺮ ﺍﻟﻜﺴﺮ ﺃﻭ ﺍﻷﻫﺪﺍﻑ ﺍﻟﻌﻼﺟﻴﺔ ﻷﻣﺮﺍﺽ
ﺍﻟﻌﻈﺍﻡ ﻓﻲ ﻣﺮﺽ ﺍﻟﺴﻜﺮﻱ ﺍﻟﻨﻮﻉ ﺍﻟﺜﺎ .ﻴ .ﻛﺸﻔﺖ ﻫﺬﻩ ﺍﻟﺪﺭﺍﺳﺔ ﺃﻧﻪ ﻓﻲ  8ﺃﺳﺎﺑﻴﻊ ﻣﻦ ﻣﺪﺓ ﺍﻹﺻﺎﺑﺔ
ﺑﻤﺮﺽ ﺍﻟﺴﻜﺮﻱ ﺍﻟﻨﻮﻉ ﺍﻟﺜﺎ ﻧﻴ ،ﺍﻟﺘﻨﻈﻴﻢ ﺍﻟﻤﺨﺘﻟ ﻓﻲ ﺍﻟﻤﺎﻳﻜﺮﻭ ﺁﺭ ﺇﻥ ﺇﻳﻪ ،20a-ﺍﻟﻤﺍﻳﻜﺮﻭ ﺁﺭ ﺇﻥ ﺃﻳﻪ-
 ،21ﺍﻟﻤﺍﻳﻜﺮﻭ ﺁﺭ ﺇﻥ ﺃﻳﻪ ،29a-ﺍﻟﻤﺍﻳﻜﺮﻭ ﺁﺭ ﺇﻥ ﺃﻳﻪ ،31-ﻭ ﺍﻟﻤﺍﻳﻜﺮﻭ ﺁﺭ ﺇﻥ ﺃﻳﻪ 155-ﺃﺛﺮ ﻋﻠﻰ ﺩﻭﺭﺓ
ﺇﻋﺎﺩﺓ ﺗﺸ ﻜﻳﻟ ﺍﻟﻌﻈﺍﻡ ﻋﻦ ﻁﺮﻳﻖ ﻗﻤﻊ ﺧﻼﻳﺎ ﺗﻜﻮﻳﻦ ﺍﻣﺘﺼﺎﺹ ﺍﻟﻌﻈﻢ ﻭ ﺧﻼﻳﺎ ﺗﻜﻮﻳﻦ ﺗﻜﻮﻥ ﺍﻟﻌﻈﻢ.
ﻓﻲ ﺍﻝ  10ﺃﺳﺎﺑﻴﻊ ﻣﻦ ﻣﺪﺓ ﺍﻹﻹﻹﺑﺔ ﺑﻤﺮﺽ ﺍﻟﺴﻜﺮﻱ ﺍﻟﻨﻮﻉ ﺍﻟﺜ ﺍﻧﻳ ،ﺍﻟﺘﻨﻈﻴﻢ ﺍﻟﻤﺨﺘﻟ ﻓﻲ ﺍﻟﻤﺍﻳﻜﺮﻭ ﺁﺭ
ﺇﻥ ﺇﻳﻪ ،20a-ﺍﻟﻤﺍﻳﻜﺮﻭ ﺁﺭ ﺇﻥ ﺃﻳﻪ ،21-ﺍﻟﻤﺍﻳﻜﺮﻭ ﺁﺭ ﺇﻥ ﺃﻳﻪ ،29a-ﺍﻟﻤﺍﻳﻜﺮﻭ ﺁﺭ ﺇﻥ ﺃﻳﻪ ،31-ﻭ
ﺍﻟﻤﺍﻳﻜﺮﻭ ﺁﺭ ﺇﻥ ﺃﻳﻪ 155-ﺃﺛﺮﻋﻞﻰ ﺩﻭﺭﺓ ﺇﻋﺎﺩﺓ ﺗﺸﻜﻴﻞ ﺍﻟﻌﻈﺎﻡ ﻋﻦ ﻁﺮﻳﻖ ﻗﻤﻊ ﺧﻼﻳﺎ ﺗﻜﻮﻳﻦ ﺍﻣﺘﺼﺎﺹ
ﺍﻟﻌﻈﻢ ﻭ ﻼ.ﻳﺎ ﺗﻜﻮﻳﻦ ﺗﻜﻮﻥ ﺍﻟﻌﻈﻢ .ﻓﻲ ﺍﻝ  44ﺃﺳﺒﻮﻉ ﻣﻦ ﻣﺪﺓ ﺍﻹﺻﺎﺑﺔ ﺑﻤﺮﺽ ﺍﻟﺴﻜﺮﻱ ﺍﻟﻨﻮﻉ
ﺍﻟﺜﺍﻧﻲ ،ﺍﻟﺘﻨﻈﻴﻢ ﺍﻟﻤﺨﺘﻟ ﻓﻳ ﺍﻟﻤﺍﻳﻜﺮﻭ ﺁﺭ ﺇﻥ ﺇﻳﻪ ،20a-ﺍﻟﻤﺎﻳﻜﺮﻭ ﺁﺭ ﺇﻥ ﺃﻳﻪ ،21-ﺍﻟﻤﺍﻳﻜﺮﻭ ﺁﺭ ﺇﻥ ﺃﻳﻪ-
 ،29aﺍﻟﻤﺍﻳﻜﺮﻭ ﺁﺭ ﺇﻥ ﺃﻳﻪ ،31-ﻭ ﺍﻟﻤﺍﻳﻜﺮﻭ ﺁﺭ ﺇﻥ ﺃﻳﻪ 155-ﺃﺛﺮ ﻋﻠﻰ ﺩﻭﺭﺓ ﺇﻋﺎﺩﺓ ﺗﺸﻜﻴﻞ ﺍﻟﻌﻈﺎﻡ ﻋﻦ
ﻁﺮﻳﻖ ﻗﻤﻊ ﺧﻼﻳﺎ ﺗﻜﻮﻳﻦ ﺍﻣﺘﺼﺎﺹ ﺍﻟﻌﻈﻢ ﻭ ﺧﻼﻳﺎ ﺗﻜﻮﻳﻦ ﺗﻜﻮﻥ ﺍﻟﻌﻈﻢ .ﻋﻼﻭﺓ ﻋﻠﻰ ﺫﻟﻚ ،ﻳﻤﻜﻦ
ﺍﺳﺘﺨﺪﺍﻡ ﻣﺎﻳﻜﺮﻭ ﺁﺭ ﺇﻥ ﺃﻳﻪ 21-ﻭ ﻣﺎﻳﻜﺮﻭ ﺁﺭ ﺇﻥ ﺃﻳﻪ 155-ﻛﻣﺆﺷﺮﺍﺕ ﺣﻴﻮﻳﺔ ﻣﺤﺘﻣﻠﺔ ﻓﻲ ﻣﺼﻞ ﺍﻟﺪﻡ.
ﺗﺸﻴﺮ ﺍﻟﺪﺭﺍﺳﺔ ﺃﻳﻀﺎ ً ﺇﻟﻰ ﺃﻥ ﻁﻮﻝ ﻣﺪﺓ ﺍﻹﺻﺎﺑﺔ ﺑﻤﺮﺽ ﺍﻟﺴﻜﺮﻱ ﺍﻟﻨﻮﻉ ﺍﻟﺜﺎﻧﻲ ﻳﺆﺛﺮ ﺳﻠﺒﺎ ً ﻋﻠﻰ ﺍﻟﻌﻈﺎﻡ،
ﻣﻣﺎ ﻳﺸﻴﺮ ﺇﻟﻰ ﺯﻴﺍ ﺩﺓ ﻫﺸﺍﺸﺓ ﺍﻟﻌﻈﺍﻡ.

مفاهيم البحث الرئيسية :ﻣﺮﺽ ﺍﻟﺴﻜﺮﻱ ﺍﻟﻨﻮﻉ ﺍﻟﺜﺎﻧﻲ ،ﻣﺮﺽ ﻫﺸﺍﺸﺔ ﺍﻟﻌﻈﺍﻡ ،ﺩﻭﺭﺓ ﺇﻋﺎﺩﺔ
ﺗﺸﻜﻴﻞ ﺍﻞﻌﻈﺎﻡ ،ﻣﺎﻳﻜﺮﻭ ﺁﺭ ﺇﻧﺎﺕ.
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Chapter 1: Introduction
1.1 Background
A healthy skeleton is maintained by being remodeled constantly; since the bone
is an active tissue (Feng & McDonald, 2011). The bone serves as a reservoir for
calcium and phosphate, protector of the vital organs, and support provider for the
muscle’s attachment sites (Feng & McDonald, 2011). The type of bone that provides
protection and responsible for the mechanical function is the cortical bone, which is
stiffer with high resistance to bending, whereas the other type of bone that provides
strength and responsible for the metabolic function is the trabecular bone, which is
spongy and has good absorbing forces (Feng & McDonald, 2011).
1.1.1 Anatomy of the Bone
Bones can be classified according to their shapes as long bones, short bones,
flat bones, and irregular bones are the main four categories of the bones (Clarke, 2008).
Overall of 80% of cortical bone and 20% of cancellous bone [trabecular bone] is the
composition of the adult human skeleton (Clarke, 2008). Figure 1 illustrates an
example of a long bone showing the cortical and cancellous bone. The cortical and
cancellous bone is what the adult human skeleton is composed of, and according to the
skeletal site, their proportions vary (Compston et al., 2019). The diaphysis of the long
bones generally contains cortical bone and epiphysis has a predominantly trabecular
bone (Compston et al., 2019).
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Figure 1: A cross-section of a proximal femur (posterior view).
Articular cartilage is a thin layer of hyaline cartilage that covers the end part of a
long bone, which functions by acting as a shock absorber; to reduce friction
(OpenStax, 2013a). The outer surface of the cortical bone is surrounded by a fibrous
connective tissue sheath called the periosteum (OpenStax, 2013a).

The functional building block of a bone is the osteon (Clarke, 2008). The
osteon is formed as an end-product of a bone remodeling cycle (Clarke, 2008). The
bone remodeling cycle benefits the bone by preserving its mechanical strength, and
that is achieved by replacing the bones which are old and have microdamage with new
healthy bones, as well as maintaining the calcium and phosphate homeostasis (Clarke,
2008). Osteoclasts and osteoblasts are the key players in the bone remodeling cycle
(Clarke, 2008). Simply, the osteoclasts are defined as the cells that are capable of
resorbing the bone, while the osteoblasts are defined as the cells that are capable of
forming the bone (Clarke, 2008).
1.2 Bone Remodeling Cycle
The process of bone remodeling works by replacing an old or damaged bone
with a new bone, and that results in every 10 years a continuous renewal of the skeleton
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(Compston et al., 2019). A Bone Remodeling Unit (BRU) or Basic Multicellular Unit
(BMU) is defined as a group of bone cells that removes and replaces one bone
structural unit (osteon) (Compston et al., 2019). At the bone remodeling units, bone
resorption takes place, bone resorption is the process by which osteoclasts break down
the bone tissue (Compston et al., 2019). This process is critical in the maintenance of
blood calcium levels. Abnormal increases in the activity of osteoclasts that produce an
increase in bone resorption cause osteoporosis and other bone loss-associated diseases
(Compston et al., 2019). Simultaneously within the resorption cavity, the bone
formation and mineralization of the new bone is a function of the osteoblasts
(Compston et al., 2019). These events are always sequenced as bone resorption
followed by bone formation, and these two processes are both specific to the site and
specific for a fixed time (Compston et al., 2019). Remodeling balance is defined as the
equal quantities of the bone resorbed compared to the bone formed, as observed in the
young adult skeleton (Compston et al., 2019). During skeletal development, the bones
are structured by the process of bone modeling for the optimization of their structure
to fight against any mechanical stress (Compston et al., 2019).
1.2.1 Phases of Bone Remodeling Cycle
1.2.1.1 Activation
Certain trauma like bone injury or bone damage may trigger the activation of
the bone remodeling cycle via various initiation factors that recruit the precursors of
osteoclast and osteoblast (Kenkre & Bassett, 2018). The initiation factors can be
paracrine factors which are released when the osteocytes undergo apoptosis and travel
through the dendritic processes of the apoptotic osteocytes (Kenkre & Bassett, 2018).
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After initiation, numerous mononuclear pre-osteoclasts [come from the
monocyte/macrophage lineage] fuse together to make multinucleated preosteoclasts
which will bind to the area of resorption (Walsh, 2017). M-CSF [macrophage colonystimulating factor] and RANKL [receptor activator of nuclear factor-kappa-Β ligand]
act as an activator to initiate the multinucleated preosteoclasts mediated dissolution of
bone (Walsh, 2017). These multinucleated cells secrete hydrochloric acid to dissolve
the bone mineral and cathepsin K to digest the bone matrix (Hadjidakis & Androulakis,
2006).
1.2.1.2 Resorption
Once the multinucleated preosteoclasts got activated by M-CSF and RANKL,
they will differentiate into osteoclasts [bone resorption cells] that will bind to the site
of resorption and form a ruffled border, which then starts the secretion of the acids and
the proteolysis enzymes (Hadjidakis & Androulakis, 2006). The duration of the
resorption phase is regulated; so that there is no excess of resorption, and that’s by
apoptosis of the osteoclasts (Kenkre & Bassett, 2018).
1.2.1.3 Reversal
It is the phase when the switch happens from bone resorption to bone formation
(Kenkre & Bassett, 2018). Osteoclasts release osteogenic signals to trigger the
mesenchymal cells [known as the reversal cells] to form cement lines, which are the
bridge that connects the resorbing osteoclasts and the bone-forming osteoblasts
(Delaisse, 2014). However, the mechanism of the reversal phase is not fully
understood (Kenkre & Bassett, 2018).
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1.2.1.4 Formation
Osteoblasts are differentiated from the mesenchymal stem cell lineage and
have two main functions: 1) synthesis of osteoid matrix [type 1 collagen-rich] and 2)
regulation of matrix mineralization (Kenkre & Bassett, 2018). The canonical Wnt
signaling pathway is the one controlling the osteoblastogenesis. In this phase, osteoid
covers the site of resorption, and osteoid mineralization [in form of hydroxyapatite
crystals] is started (Crockett et al., 2011).
1.2.1.5 Termination
The complete osteoid matrix mineralization triggers the osteoblasts either to be
trapped into their mineralized matrix and differentiate into osteocytes or to be changed
into bone-lining cells by undergoing programmed cell death (Crockett et al., 2011).
1.3 Disorders of Bone Remodeling
1.3.1 Osteoporosis
Osteoporosis is a skeletal disorder in which the patient’s bone quantity and
quality are affected (Dougherty, 1996). Bone quantity measures bone mineral density
whereas bone quality measures the adherence and microstructural deterioration of the
bone’s internal architecture (Dougherty, 1996). Osteoporosis can be defined as a
systemic skeletal disease, resulting in micro-architectural deterioration (Eastell, 2013).
Some of the key characteristics are low bone mass, notable elevation in bone fragility,
and vulnerability to fractures (Eastell, 2013). The most severely affected regions are
the pelvic region, vertebral column, and limbs (Eastell, 2013). Moreover, it is also
defined based on the bone mineral density [BMD] as such the comparison of the bone
mineral density between an older person and a younger person is measured by
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determining the standard deviation units by Dual-energy X-ray absorptiometry
(DEXA) [T-score ≤ - 2.5 is considered as having osteoporosis] (Eastell, 2013). The
fractures of osteoporotic individuals cause noticeable morbidity and mortality [in the
first year following a hip fracture, the mortality rate is elevated by 20%] (Eastell,
2013). Kyphosis, abdominal protrusion, and loss of height are deformities that result
from osteoporosis (Eastell, 2013). The imbalance of the rates between bone resorption
and bone formation is the cause of the bone loss, which ends up in the perforation and
the thinning of the bones that modify its architecture and losing its strength (Eastell,
2013). There are two mechanisms by which osteoporosis roles: 1) high turnover
osteoporosis that is defined by significantly elevated levels of bone resorption and
bone formation, and 2) low turnover osteoporosis that is known by a notably drop in
the levels of bone resorption and bone formation (Heinz, 1992). Scientists have
classified osteoporosis into primary type 1 osteoporosis and primary type 2
osteoporosis according to the bone turnover rate. Primary type 1 is post-menopausal
osteoporosis in females that is categorized as high bone turnover, which is caused by
a deficiency in estrogen or androgen levels in the blood, and primary type 2 is senile
osteoporosis in both sexes that is recognized by low bone turnover, which results from
aging, or in scientific words, senescence of body cells (Heinz, 1992). Secondary
Osteoporosis develops when certain medical conditions and medications increase bone
remodeling leading to disruption of bone reformation (Heinz, 1992). The loss of bone
mass occurs due to the imbalance between the production of new bone and the loss of
old bone, leading to lower bone turnover rate (Heinz, 1992). In other words, some of
drugs and diseases may lead to osteoporosis as a side effect, it is known as secondary
osteoporosis, and its mechanism of action is not clearly understood, whether it is a
high or low bone turnover which differs specifically in each disorder (Heinz, 1992).
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1.3.2 Examples of Secondary Osteoporosis
Rheumatoid arthritis, asthma, and multiple sclerosis are treated commonly with
immunomodulatory drugs called “Glucocorticoids” (Feng & McDonald, 2011). Low
bone mass and increased fracture risk are the most significant complications of the
prolonged therapeutic use of glucocorticoids, which then leads to secondary
osteoporosis called glucocorticoid-induced osteoporosis (Feng & McDonald, 2011).
Those glucocorticoids inhibit osteoblast differentiation that leads to suppression of
bone formation, and elevation in bone resorption, which results in an imbalance of the
bone remodeling cycle leading to a decrease in bone mass (Feng & McDonald, 2011).
Another example of secondary osteoporosis is immobilization-induced
osteoporosis, which is defined as the prolonged decrease in mechanical demands
results in impaired mechanical strength of the bones, which affects its mechanical
loading or weight-bearing (Feng & McDonald, 2011). However, the mechanism of
immobilization-induced osteoporosis is not completely understood (Feng &
McDonald, 2011).
1.4 Epidemiology of Osteoporosis in Type 2 Diabetic Individuals
1.4.1 Type 2 Diabetes Mellitus
The endocrine portion of the pancreas is represented by the islets of
Langerhans, and those secrete hormones directly into the bloodstream without going
through a duct (OpenStax, 2013b). There are four types of islets of Langerhans: 1)
alpha cells [secrete glucagon], 2) beta cells [secrete insulin], 3) delta cells [secrete
somatostatin] and 4) PP cells [secrete pancreatic polypeptide hormone] (OpenStax,
2013b). The elevated levels of blood glucose, blood amino acids, blood fatty acids,
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and gastrointestinal hormones from the upper gastrointestinal (GI) tract stimulate the
somatostatin secretion, while insulin and catecholamines inhibit the somatostatin
secretion (OpenStax, 2013b). Somatostatin inhibits gastrointestinal, endocrine,
exocrine, pancreatic, and pituitary secretions (OpenStax, 2013b). The pancreatic
polypeptide hormone regulates the pancreatic exocrine and endocrine secretions and
plays a major role in appetite (OpenStax, 2013b).
The molecular weight of the insulin is around 6000 Daltons, which is a
relatively small protein that has two chains kept united by disulfide bonds, and among
vertebrates, the sequence of the amino acid is highly conserved (Humbel, 1966).
Preproinsulin is a single chain precursor that is translated from the insulin mRNA, and
during the insertion of the preproinsulin into the endoplasmic reticulum, it gets cleaved
to become proinsulin (Humbel, 1966). In addition, the proinsulin is further cleaved
within the endoplasmic reticulum by endopeptidases to form insulin [the mature form]
and free C peptide, which then packaged into secretory granules in the Golgi and
accumulates in the cytoplasm (Humbel, 1966). When an appropriate stimulus is
present, the beta cells secrete insulin along with free C peptide by exocytosis, and
insulin binds to the receptors of the target cells (Humbel, 1966). The secretion of
insulin is regulated through four different factors: 1) hyperglycemia [the insulin will
be secreted to return the body to normoglycemia], 2) hyperaminoacidemia [the beta
cells are stimulated by arginine and lysine; to elevate the secretion of insulin, and the
insulin will lower the number of amino acids in the plasma by promoting their entry
into the cells and enhancing protein synthesis], 3) the insulin level is increased in the
presence of the fatty acids and ketone bodies, and 4) hormones as well increase the
level of insulin [for instance, glucagon, gastrin, cortisol, growth hormone, gastric
inhibitory peptide, secretin and cholecystokinin] (OpenStax, 2013b). The insulin
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affects carbohydrate metabolism by storing the glucose as glycogen in the liver,
making more of stored glycogen in the liver [glycogenesis], inhibiting glycogenolysis
and gluconeogenesis, and converting the increased glucose in the liver to fatty acids
(OpenStax, 2013b). Insulin has a role in fat metabolism by suppressing the hormonesensitive lipase from breaking down the fats and promoting glucose transport into the
adipocytes (OpenStax, 2013b). Insulin has a crucial part on protein metabolism by
lowering the gluconeogenesis rate in the liver, halting the protein catabolism, rising
the transcription rate of DNA and the translation rate of mRNA to synthesize new
proteins, and enabling an active transport of a lot of amino acids into the cells
(OpenStax, 2013b).
Type 2 diabetes mellitus is characterized by chronic hyperglycemia, which is
caused by insulin resistance along with defective insulin secretion (Ling et al., 2019).
Moreover, aging, unhealthy lifestyle, and obesity are well-established cause for insulin
resistance, and the impaired insulin secretion happened due to the long-term exposure
of hyperglycemia, which altered the ability of the pancreatic β-cells to secrete insulin
(Chatterjee et al., 2017; Davegårdh et al., 2018; Ling & Ronn, 2019). Studies have
shown that the pancreatic β-cells dysfunction is due to its destruction by the ongoing
apoptosis (Taylor et al., 2019). Furthermore, type 2 diabetic patients will develop some
complications such as osteoporosis, which makes them more susceptible to fractures
and thus take more than the normal time of healing (Bhamb et al., 2019). Type 2
diabetes mellitus may lead to osteoporosis; since it disturbs the bone remodeling cycle
(Bhamb et al., 2019).
1.4.2 Prevalence of Fracture Risk in Type 2 Diabetes Mellitus
A meta-analysis was conducted for 16 epidemiologic studies; to find an
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association between diabetes and bone fractures, this systematic review revealed that
there was a strong association between type 2 diabetes mellitus and elevated risk of
hip fractures in both men and women (Janghorbani et al., 2007). Another meta-analysis
was performed for 30 epidemiologic studies; to detect an association between diabetes
mellitus and bone fractures, this systematic review reported that there was a strong
association between T2DM and increased overall fracture risk, emphasizing that
strategies should be implemented to prevent fractures in type 2 diabetic patients
(Moayeri et al., 2017).
A cross-sectional, single-center study was done by the Heidelberg Study
Center in collaboration with the European Vertebral Osteoporosis Study for the
diabetic patients from the outpatient clinic at the University of Heidelberg revealed
that out of 325 diabetic patients, 12 of them had serious-traumatic bone fractures and
17 of them had low-traumatic bone fractures (Leidig-Bruckner et al., 2014).
Furthermore, a cross-sectional study was done from 24 tertiary hospital diabetes clinics
in Korea stated that 43.3% of post-menopausal women with T2DM had vertebral
fractures (Chung et al., 2013).
A historical cohort study was performed on the Rochester residents with T2DM
stated that 1369 bone fractures were experienced by 700 diabetic residents,
emphasizing that among the diabetic Rochester residents, the overall fracture risk was
increased (Melton et al., 2008). In addition to that, a retrospective cohort study stated
that patients with T2DM who received insulin as a treatment, are at a high risk of
getting bone fractures (Monami et al., 2008). It’s been reported that 30% of T2DM
patients got low-traumatic bone fractures, based on a questionnaire from a Moscow
outpatient clinic (Yalochkina et al., 2016).

11
Recent research by Dr. Sahar’s research group at UAEU has shown a
suggestion that T2DM affects the trabecular structure within a rat’s femoral heads
negatively and changes are most significant at a longer duration of T2DM, increasing
the risk of hip fractures (Mohsin et al., 2019).
1.5 Statement of the Problem
Currently, a widely used clinical technique for the diagnosis of osteoporosis is
the DEXA scan where bone density/quantity is measured (Rossini et al., 2016).
Additionally, some of the biochemical tests available as a biomarker for osteoporosis
are non-specific (Lorentzon & Cummings, 2015). The available biomarkers have poor
sensitivity and specificity for several reasons. For instance, alkaline phosphatase,
osteocalcin, pro-peptides of type I procollagen are considered as bone formation
markers, and pyridinoline, deoxypyridinoline, N- and C-terminal telopeptides of type
I collagen are considered as bone resorption markers (Rossini et al., 2016). But these
biomarker levels are altered due to several other disorders and diseases. For example,
elevated serum alkaline phosphatase does not always mean that the patient has a bone
disease since the alkaline phosphatase is also considered as a hepatic marker
(Mukaiyama et al., 2015). Moreover, osteocalcin is mainly produced by osteoblasts,
its carboxylated form regulates mineralization by acting in the bone matrix (Zoch et
al., 2016). But, the undercarboxylated form of osteocalcin acts in the β-cells of the
pancreas to enhance the production and secretion of insulin, acts in the brain to enhance
the production of neurotransmitters, acts in the adipose tissue to enhance insulin
sensitivity, and acts in the testes to start the production of testosterone (Zoch et al.,
2016). Although its carboxylated form might be useful for the diagnosis of
osteoporosis, it cannot be used exclusively to rule out osteoporosis without DXA
(Singh et al., 2015). In addition, pro-peptides of type I procollagen, pyridinoline,
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deoxypyridinoline, N- and C-terminal telopeptides of type I collagen are well-known
biochemical markers for bone, but because of their poor specificity, they cannot be
used to screen for osteoporosis, rather they are used to for monitoring purposes of
antiresorptive therapies (Zaitseva et al., 2015).
Recent studies have shown that a new class of RNAs i.e. miRNA can also be
used as a biomarker for various diseases such as liver disease, pancreatic cancer, viral
diseases (Bandiera et al., 2015; Cui et al., 2020; Gokita et al., 2020; Huang, 2017).
Recently their use as a biomarker in bone-related diseases is also being investigated
like osteoporosis (Foessl et al., 2019). The purpose of this study is to investigate the
altered expression of (if any) microRNAs that are known to have a role in bone
formation and bone resorption in the bones and sera of type 2 diabetic rats. The current
study will help in revealing the mechanisms of skeletal fragility in type 2 diabetes. The
knowledge gained in this research will be beneficial in enriching the medical field with
the potential to use microRNAs as diagnostic biomarkers or therapeutic targets for type
2 diabetic osteopathy.
1.6 The Role of MicroRNAs in Bone Resorption and Bone Formation
1.6.1 Definition of MicroRNAs
Micro-RNAs [miRNAs] are small RNAs [about 20 – 25 nucleotides long] that
are called sometimes as small temporal RNAs [stRNAs]; because during development,
their existence is temporary (Nelson & Cox, 2005). MiRNAs function as a posttranscriptional modulator, causing the silencing of its target known as RNA inference
(Nelson & Cox, 2005). The 3` untranslated region (UTR) of the mRNA has some
specific binding sites for various miRNAs, known as seed sequence (Nelson & Cox,
2005). Seed sequence is a region where the interaction takes place with 5’ end of
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miRNAs (Nelson & Cox, 2005). Consequently, the mRNA is halted from being
translated as a result of mRNA degradation or translational inhibition, and the gene
that produces the mRNA is silenced (Nelson & Cox, 2005).
1.6.2 Biogenesis of MicroRNAs
MiRNAs are synthesized in the nucleus by RNA polymerase II enzyme in a
similar manner to mRNAs (Berg et al., 2015). RNA polymerase II requires two
specific promoter regions to initiate the synthesis of genes (transcription) (Berg et al.,
2015). The RNA polymerase II first binding site is upstream of the transcription start
site, known as the TATA box and the second one is known as DPE (downstream
promoter element), which can be coupled with CAAT box and GC Box (Berg et al.,
2015). These are the regulatory sequences of the transcription initiation (Berg et al.,
2015). The RNA polymerase II promoter has an enhancer element upstream of the start
site, which stimulates the transcription (Berg et al., 2015).
The transcript is a primary microRNA, which will fold to form a typical stem
and loop structure, it will become the final mature microRNA with its regulatory
function after several steps of processing (Watson et al., 2014). First, the doublestranded stem is recognized by the protein DGCR8 [PASHA], an enzyme called
DROSHA is associated with the protein DGCR8 [PASHA] to form a microprocessor
complex, which can cleave the primary microRNA into a smaller precursor microRNA
that can be exported into the cytoplasm where it will inactivate the mRNA of one or
multiple genes (Watson et al., 2014). The precursor microRNA is carried out of the
nucleus through a nuclear pore by a transporter molecule EXPORTIN 5 (Watson et
al., 2014). In the cytoplasm, it is recognized by a large RNA protein called DICER, it
chops the head of the stem and loop structure; to forms a short double-stranded
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microRNA molecule (Watson et al., 2014). In the next step, an argonaute protein AGO
2 interacts with DICER; to bind the short double-stranded microRNA, which then is
unwound and one strand is released, the remaining strand called the guide strand
interacts with AGO 2 and some additional proteins to form the RISC [RNA induced
silencing complex], it can be now guided to its target mRNA and inactivate one or
multiple genes (Watson et al., 2014). The biogenesis of microRNAs is illustrated in
Figure 2.

Figure 2: Biogenesis of microRNAs.
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1.6.3 Gene Regulation by MicroRNAs
The mRNA of a target gene is complementary to the sequence of the
microRNA that enables base pairing. Once bounds, there are two ways in which RISC
can inactivate the mRNA, proteins in the complex can simply degrade the mRNA,
which will be further destroyed by the cell (Watson et al., 2014). Blocking of
translation is another mechanism, the RISC complex prevents the ribosome subunit
from binding (Watson et al., 2014). In both cases, the mRNA will not be translated
into a protein and the gene is silenced.
1.6.4 The Bone Remodeling Cycle is Regulated by MicroRNAs
Micro-RNAs activate bone remolding and regulation of osteoclast
differentiation by controlling the signaling pathways that operate these events, for
instance, the micro-RNAs can target the macrophage colony-stimulating factor [MCSF] signaling pathway and the receptor activator of NF-κB ligand [RANKL] (Loh et
al., 2018). Furthermore, there are micro-RNAs involve in bone formation as well by
targeting the pathway that turns the mesenchymal stem cells into osteoblast lineage,
which is the canonical Wnt/β-catenin signaling pathway (Loh et al., 2018). In order
for the Wnt-responsive gene to be expressed, the β-catenin has to be stabilized for
regulating the function of the osteoblast by targeting many Wnt-signaling pathway
inhibitors; to act as a positive regulator of osteoblast differentiation (Loh et al., 2018).
1.7 Literature Review
1.7.1 MicroRNA-20a
Some of the miRNAs are involved in the regulation of the self-clearing of cells
known as Autophagy (Che et al., 2019). For instance, miRNA-20a have a role in
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hypoxia regulation, a research stated that upon HIF-1α (Hypoxia-inducible factor 1alpha) accumulation, there was a significant drop in miR-20a expression. This study
suggests that HIF-1α is targeted by miR-20a (Che et al., 2019). There is a negative
correlation between the expression of miR-20a and HIF-1 α mediated
autophagy/lysosome pathway (Che et al., 2019). Previous researches have established
the direct targeting of ATG16L1 (Autophagy related 16 like 1) by miR-20a resulting
in the defects of hypoxia-induced autophagy in osteoclast differentiation (Sun et al.,
2015). ATG5 and FIP200 are two proteins that are essential for autophagosome
formation, and it is noticed that the overexpression of miR-20a strongly decreases
those two proteins and the mRNA levels (Che et al., 2019). Through increasing the
expression of ATG5 and FIP200, the down-regulation of hypoxia-induced miR-20a is
facilitated (Che et al., 2019). Another study shows that some of the members of the
E2F family that are set of genes tangled with DNA synthesis and cell cycle regulation
are targeted by miR-20a, which promotes proliferation, sustains cell survival, and
increases angiogenesis (Che et al., 2019). Similarly, mir-20a is known to regulate cell
growth (Torbati et al., 2019). Furthermore, the key regulatory mechanisms involved
in osteoblastogenesis and differentiation are Wnt, BMP, and TGF-β signaling
pathways (Bellavia et al., 2019). Interestingly, miR-20a is a regulatory factor for the
Wnt, BMP, and TGF- β signaling pathways (Bellavia et al., 2019). In the Wnt signaling
pathway, the expression of miR-20a inhibits the Peroxisome Proliferator-Activated
Receptor Gamma [PPARG] that is involved in the differentiation of adipocytes, which
will lead to the promotion of osteoblast differentiation (Bellavia et al., 2019). The Wnt
signaling pathway is controlling osteoblasts formation by affecting the bone density
through inactivating mutations in Wnt pathway components (Lodish et al., n.d.). In the
BMP signaling pathway, the expression of miR-20a suppresses Bone Morphogenetic
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Proteins and Activin Membrane-Bound Inhibitor [BAMBI] and Cysteine-Rich Motor
Neuron 1 [CRIM1], which are controlling the signal transduction during
developmental processes, and that’s lead to the promotion of osteoblast differentiation
(Bellavia et al., 2019). In the TGF-β signaling pathway, the expression of miR-20a
blocks TGF-β Receptor 2 [TGFBR2] and Lysine-specific demethylase 6b [KDM6B],
which the earlier involved in the regulation of cell proliferation and the latter involved
in the cell differentiation, and that will lead to the promotion of osteoblast
differentiation (Bellavia et al., 2019).
1.7.2 MicroRNA-21
MicroRNA-21 has a role in inducing osteoblast differentiation through BMP,
TGF-β, and MAPK pathways, and also has a role in inhibiting osteoclast
differentiation through the RANK pathway (Bellavia et al., 2019). In the BMP
signaling pathway, the expression of miR-21 blocks the production of SMAD7, which
is known to inhibit osteoblast differentiation (Bellavia et al., 2019). A study has shown
that partial dysfunction of SMAD7 disturbs bone remodeling by impairing
osteogenesis (Li et al., 2014). Moreover, SMAD7 is also blocked by the expression of
miR-21 through the TGF-β pathway (Bellavia et al., 2019). Furthermore, the MAPK
cascade activation is prevented by the expression of miR-21, and that leads to a
decrease in the level of Sprouty homolog 1 [SPRY1] (Bellavia et al., 2019). In
adipocytes, the SPRY1 is expressed to act as a protector from high-fat diet-induced
obesity and associated bone loss (Urs et al., 2012). So, the decreased level of SPRY1
will promote osteoclastogenesis by inhibiting the RANKL level and promoting the
OPG level (Hu et al., 2017). Receptor activator of nuclear factor κB ligand (RANKL)
is known to induce expression of miR-21, and its silencing suppresses
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osteoclastogenesis (Sugatani et al., 2011). In the RANK pathway, the mRNA of c-FOS
and its protein phosphorylation level is down-regulated; because of the inhibited
expression of Programmed Cell Death Protein 4 [PDCD4] by the expression of miR21, which results in promoting bone resorption (Hu et al., 2017).
1.7.3 MicroRNA-29a
MicroRNA-29a has a role in promoting osteoblast differentiation through Wnt,
Matrix mineralization, and RUNX2 pathways and has a protective role from
osteoporosis by repressing osteoclast regulator RANKL (Bellavia et al., 2019; Lian et
al., 2019). Past researchers stated that miR-29a negatively regulates the negative
regulators of the osteoblasts: Dikkopf 1 [DKK1], Kringle Containing Transmembrane
Protein 2 [KREMEN2], and Secreted Frizzled Related Protein 2 [SFRP2] of the Wnt
signaling pathway (Alfaro et al., 2010; Bellavia et al., 2019; Pinzone et al., 2009;
Schulze et al., 2010). The Osteonectin [ON], which is a non-collagenous matrix protein
that plays a vital role in matrix mineralization during osteogenesis, it is shown to be
targeted by miR-29a, leading to accelerating extracellular mineralization response
(Bellavia et al., 2019). Another study suggests that the inhibition of miR-29a leads to
overexpression of TGFB1 [Transforming Growth Factor Beta 1], which results in an
increased level of ON (James et al., 2014). Also, miR-29a protects RUNX2, which is
involved in bone development, from deacetylation, by down-regulating the levels of
Histone Deacetylase 4 [HDAC4] (Jonason et al., 2009; Ko et al., 2015).
1.7.4 MicroRNA-31
Sequence-binding protein 2 [SATB2] has a role in the transcriptional
regulation of osteoblast differentiation (Baglìo et al., 2013). MicroRNA-31 targets the
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mRNA of SATB2 [involved in preventing the imperfection in the osteoblast function]
as well as RUNX2, consequently blocking osteoblast differentiation, and that
effectively reduces the stability of the osteoblast-specific transcription factor Osterix
(SP7) (Baglìo et al., 2013; Jin Zhang et al., 2011). This reduction in SP7 expression
implicates the expression of osteoblast effector genes (Baglìo et al., 2013). In the
literature review, the inhibition of miR-31 is determined to increase the expression of
SP7, which promotes osteoblast differentiation (Baglìo et al., 2013). In addition,
another research describes the considerable fall in the number of tartrate-resistant acid
phosphatase [TRAP]-positive multinucleated osteoblastic cells upon suppression of
miR-31 via specific antagomirs under receptor activator of NF-κB ligand (RANKL)
treatment (Loh et al., 2018). Moreover, in osteoclastogenesis, Ras homolog family
member A [RhoA] activates migration of osteoclast, actin polymerization and
podosome turnover (Georgess et al., 2014). Studies suggest that miR-31 downregulates RhoA which affects osteoclast formation and bone resorption (Mizoguchi et
al., 2013). On the contrary, inhibition of miR-31 promotes the expression of the RhoA
gene, which suppresses osteoclastogenesis and bone resorption (Mizoguchi et al.,
2013). Also, the thyroid gland has parafollicular cells that synthesize calcitonin-related
polypeptide alpha [CALCA] (Palmieri et al., 2007). This protein is a direct effector of
osteogenesis (Palmieri et al., 2007). MiR-31 targets the mRNA of CALCA, and that
signals for blocking osteogenesis (Palmieri et al., 2007).
1.7.5 MicroRNA-155
MicroRNA-155 has a role in suppressing osteoblast differentiation through
TNF-α and BMP pathways, whereas it involves suppressing osteoclast differentiation
through the RANK pathway (Bellavia et al., 2019). In a murine arthritis model, the
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deficiency of miR-155 suppresses osteoclastogenesis (Blüml et al., 2011). In the TNFα pathway, the Suppressor of Cytokine Signaling 1 [SOCS1] mRNA is inhibited by
the expression of miR-155 (Wua et al., 2012). SOCS1 protein downregulates cytokine
signal transduction involved in bone loss (Souza et al., 2017). Briefly, in the BMP
signaling pathway, the expression of miR-155 down-regulates SMAD5 and inhibits
osteoblast differentiation (Bellavia et al., 2019). SMAD5 is required for the formation
of endochondral bone (Retting et al., 2009). One study suggests that the role of miR155 in modulating the targets (Cathepsin K [CTSK] and Tartrate-resistant acid
phosphatase [TRAP]) of Microphthalmia-Associated Transcription Factor [MITF ]
which are involved in the osteoclast activities, thereby reducing it (J. Zhang et al.,
2012). Overexpression of miR-155 promotes cell proliferation and osteoclast
activation, which works by decreasing the expression of OPG [Osteoprotegerin] and
increasing the expression of RANK, RANKL, and TNF-α (Mao et al., 2019).
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1.7.6 Summary of the Literature Review
A summary of the literature review stating the expression of miR-20a, miR-21,
miR-29a, miR-31, and miR-155, their target genes expression, and their possible
effects on the bone remodeling cycle is shown in Table 1.
Table 1: The target genes of miR-20a, miR-21, miR-29a, miR-31, and miR-155, their
expression and effect on the bone remodeling cycle.

MicroRNA

MicroRNA
Expression

Target Gene
Expression

Effect on the Bone
Remodeling Cycle

References

↓ ATG16L1

Suppress osteoclast
differentiation

Sun et al., 2015

Promote osteoblast
differentiation

Bellavia et al., 2019

↓ SMAD7

Promote osteoblast
differentiation

Bellavia et al., 2019

↓ SPRY1

Promote
osteoclastogenesis

Hu et al., 2017

↓ PDCD4

Promote bone
resorption

Hu et al., 2017

↓ PPARG
MiR-20a

Upregulation

↓ BAMBI
↓ CRIM1
↓ TGRBR2
↓ KDM6B

MiR-21

Upregulation

↓ = The expression of the target gene is downregulated
↑ = The expression of the target gene is upregulated
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Table 1: The target genes of miR-20a, miR-21, miR-29a, miR-31, and miR-155, their
expression, and effect on the bone remodeling cycle (continued).

MicroRNA

MicroRNA
Expression

Target Gene
Expression

Effect on the Bone
Remodeling Cycle

References

Promote osteoblast
differentiation

Bellavia et al., 2019

↓ HDAC4

Promote osteoblast
differentiation

Ko et al., 2015

↓ ON

Accelerate
extracellular
mineralization

Bellavia et al., 2019

↑ TGFB1

Increased level of ON

James, Delany, &
Nair, 2014

Suppress osteoblast
differentiation

Baglìo et al., 2013

↓ CALCA

Suppress osteogenesis

Palmieri et al., 2007

↑ RhoA

Suppress
osteoclastogenesis &
bone resorption

Mizoguchi et al.,
2013

↓ SOCS1

Suppress osteoblast
differentiation

Wua et al., 2012

↓ SMAD5

Suppress osteoblast
differentiation

Bellavia et al., 2019

↓ MITF

Suppress bone
resorption

Zhang et al., 2012

Promote bone
resorption

Mao, Zhu, Hao,
Chu, & Su, 2019

↓ DKK1
↓ KREMEN2
↓ SFRP2
Upregulation
MiR-29a

Downregulation

↓ SATB2
Upregulation
MiR-31

Downregulation

MiR-155

Upregulation

↓ RUNX2
↓ SP7

↓ OPG
↑ RANK
↑ RANKL
↑ TNF-α
↓ = The expression of the target gene is downregulated
↑ = The expression of the target gene is upregulated
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1.8 Research Hypothesis
The existing evidence indicates that short non-coding RNAs known as
microRNAs (miRNAs), are the key post-transcriptional repressors of gene expression,
and growing numbers of novel miRNAs have been verified to play vital roles in the
regulation of osteogenesis, osteoclastogenesis, and adipogenesis, revealing how they
interact with signaling molecules to control these processes. The study aims to identify
the changes in miRNAs levels related to the bone remodeling cycle in bones and sera
of type 2 diabetic rats. Previous studies have shown that some microRNAs are
responsible for regulating the bone remodeling cycle, and changes in the expression of
those microRNAs will result in osteoporosis.
1.9 Aims and Objectives
Aim:
The aim of this study is to identify the changes in microRNAs expression that
are associated with the bone remodeling cycle in type 2 diabetes. Investigate the
mechanism of osteoporosis in type 2 diabetes mellitus through MicroRNAs with the
potential to be used as diagnostic biomarkers to assess fracture risk or therapeutic
targets for type 2 diabetic osteopathy.
Objective:
1. Establish a type 2 diabetic animal model.
2. Investigate the expression of miR-20a, miR-21, miR-29a, miR-31, and
miR-155 in the serum samples obtained from control and type 2
diabetic animal models.
3. Investigate the expression of miR-20a, miR-21, miR-29a, miR-31, and
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miR-155 in the bone samples obtained from control and type 2 diabetic
animal models.
4. Assess the expression of some of the target genes for the selected
microRNAs in the bones of T2DM animal models.
5. Study the bone microstructure in control and diabetic bone samples
using histological techniques.
6. Examine the bone biomarkers in the serum and bone samples obtained
from control and diabetic animals using the ELISA technique.
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Chapter 2: Methods
2.1 Animal Models
The design of this study consists of two independent groups of animal models.
The three-month-old female Wistar rats were used as the proposed animal models in
the experiments. They are closely related to humans in terms of behavioral, genetic,
and biological characteristics (Bird & Parlee, 2000). From the animal house facility at
United Arab Emirates University, those three-month-old female Wistar rats (n=96)
were obtained. Under the standard conditions with a 12 h alternating light and dark
cycle (22 – 24°C) in 50–60% humidity, the animals were individually housed in cages.
During the two weeks of acclimatization, free access to standard rat chow and water
ad libitum was provided to the animals. All efforts were made to reduce the suffering
of the animal and to minimize the number of animals used. All animal procedures were
approved by the animal ethical committee at United Arab Emirates University
[ERA_2017_5597] (Mohsin et al., 2019).
The first group is the control group and the second group is the T2DM group.
The control group contains normal three-month-old female Wistar rats (n=24) that
have been fed with normal diet (D12492 diet; Research Diets, Inc., USA) for 21 days
[during this period, the glucose test was performed for them, and they should maintain
< 100 mg/dL]. On the 7th & 14th day, a saline injection is given to all the rats. After
10 days of the last saline injection, a blood glucose test was performed on their tail
vein after fasting for 5 hours using a blood glucose meter (Accu-Chek Performa;
Roche Diagnostics, USA); to check whether they have maintained a glucose level of
< 100 mg/dL. Then, an insulin tolerance test was performed; to confirm that they lack
insulin resistance. Lastly, they have been sacrificed at 8, 10, and 14 weeks (n = 8 for
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each time interval) of the onset of being normal. All the bones have been dissected out,
cleaned and fixed, and stored at –20°C for further analysis.
The T2DM group contains normal three-month-old female Wistar rats (n=24)
that have been fed with a high-fat diet (D12492 diet; Research Diets, Inc., USA) for
21 days [during this period, the glucose test was performed for them, and the criteria
was to maintain > 100 mg/dL of glucose in blood]. On the 7th & 14th day, a
streptozocin (STZ) injection (30 mg/kg intraperitoneally) is given to all the rats. After
10 days of the last saline injection, a blood glucose test was performed on their tail
vein after fasting for 5 hours using a blood glucose meter (Accu-Chek Performa;
Roche Diagnostics, USA); to check their blood glucose levels. Those animals with
glucose levels > 270 mg/dL were considered diabetic (M. Zhang et al., 2008). Then,
an insulin tolerance test was performed; to confirm that they have insulin resistance.
Lastly, they have been sacrificed at 8, 10, and 14 weeks (n = 8 for each time interval)
of the onset of being type 2 diabetic. All the bones have been dissected out, cleaned
and fixed, and stored at –20°C for further analysis. The serum samples were
immediately withdrawn just before the animals were sacrificed, and kept in labeled
Eppendorf tubes at room temperature for 30 minutes; to clot. Then, the tubes were
centrifuged at 3,000 rpm for 10 minutes; to separate the clot from the serum. The serum
samples were kept in fresh labeled Eppendorf tubes and stored at –80°C. In this study,
the right and the left sides of the femur were used for histology, and the right and the
left sides of the tibia along with the serum samples were used for molecular biology.
2.2 Preparation of Gelatin-Coated Microscopic Slides
The regular microscopic slides are uncoated, which means that the histological
paraffin sections will detach from the slides during staining and washing steps. To
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resolve this problem, those slides were coated with adhesive compounds, such as
gelatin. To prepare gelatin-coated microscopic slides, a hot plate was used with a
magnetic stirrer to heat 1 L of distilled water at a temperature of 45°C. With the aid of
the magnetic stirrer, 3.0 g of gelatin was completely dissolved in the heated 1 L of
distilled water (temperature = 45°C). Once the gelatin was completely dissolved, 0.5
g chromium potassium sulfate dodecahydrate KCr(SO4)2·12(H2O) [the color of the
solution will be pale blue] was added. The purpose of the addition of chromium
potassium sulfate dodecahydrate was to make the slides positively charged; to allow
them to attract the tissue sections, which are negatively charged. The regular
microscopic slides were cleaned by washing them in tap water and rinsing them in
distilled water and lastly in absolute ethanol. Then, the cleaned slides were placed into
the slide racks and dipped in the gelatin-coating solution 5 times. After that, the slides
were drained from the excess solution by gently tapping the slide racks against a paper
tissue. Finally, the slides were air-dried at room temperature for 24 hours by letting
them stand on a cleaned laboratory bench covered with aluminum foil; to protect them
from the dust. Those dried slides are now gelatin-coated microscopic slides, which can
be stored in their original boxes [labeled as gelatin-coated slides] at room temperature
until use.
2.3 Bone Histology
2.3.1 Procedure of Embedding Bones into Paraffin Blocks and Sectioning Them
The paraffin sections allowed the study of bone histology using a variety of
staining techniques. The protocol consisted of fixation and decalcification of the
bones, paraffin infiltration and embedding, and eventually sectioning them.
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2.3.2 Fixation of the Bones
The proximal end of the femur [including the head of the femur] was used to
study the histological changes. The specimens were 2 mm long, and they were kept in
a small glass bottle containing 2 ml of 4% formaldehyde for 2 days. This step was
important as the fixed bones prevent autolysis. Once the 48 hours of fixation was over,
the fixed bones were washed in slowly running tap water for 30 minutes.
2.3.3 Decalcification of the Bones
The washed fixed bones were put into their separate small glass bottle
containing 2 ml of 10% EDTA for 7 days. EDTA is a decalcifying solution that works
by removing the calcium ions from the bones and making them soft and easy to section
(Savi et al., 2017). It’s been kept in mind that every day, the used decalcifying solution
should be discarded and replaced with a fresh one. During that period, every two days
a chemical test was performed for the residual calcium in the used decalcifying
solution; to check whether the decalcification was completed (Rosen, 1981). The
chemical test was done by preparing the ammonium hydroxide/ammonium oxalate
working solution, and this was achieved by adding equal parts of 5% ammonium
hydroxide solution and 5% ammonium oxalate solution (Rosen, 1981). Then, in a
clean test tube, 5 ml of the used decalcifying solution was pipetted and added to it, and
after that 10 ml of the ammonium hydroxide/ammonium oxalate working solution was
added to the same test tube (Rosen, 1981). The test tube was mixed well and let stand
for 5 minutes (Rosen, 1981). The lack of precipitate means that the decalcification was
completed, and the presence of precipitate means that the decalcification was not
completed (Rosen, 1981). To conclude that the decalcification was completed, the
status of no precipitate was observed on two consecutive days of the testing. The bones
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were washed in slowly running tap water for 30 minutes, once the decalcification was
completed.
2.3.4 Paraffin Infiltration
The washed decalcified fixed bones were put into their cassettes and labeled
those cassettes with pencil accordingly. After that, the bones were processed as
follows:1. 70% Ethanol = 1 hour.
2. 95% Ethanol = 1 hour.
3. 100% Ethanol-I = 1 hour.
4. 100% Ethanol-II = 1 hour and 30 minutes.
5. 100% Ethanol-III = 1 hour and 30 minutes.
6. 100% Ethanol-IV = 2 hour.
7. 100% Xylene-I = 1 hour.
8. 100% Xylene-II = 1 hour.
9. Paraffin wax-I at 60°C = 1 hour.
10. Paraffin wax-II at 60°C = 1 hour.
Those processed bones in the cassettes can be stored at room temperature for
an infinite time. In this step, the bones were dehydrated by series of ethanol baths; to
displace the water from the bones, and then infiltrate them with paraffin wax.
2.3.5 Paraffin Embedding
Paraffin embedding is the step where the paraffin blocks of the processed bones
can be created. It’s been done according to the following steps:1. The cassette was opened by discarding the cassette lid.
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2. The correct metal mold was chosen. The decision was made depending on the
size of the tissue.
3. The mold, the forceps, and the opened cassette that contained the processed
tissue with paraffin were placed on a hot plate at 60°C. Note that the paraffin
in the opened cassette will be melted.
4. By using the forceps, the tissue was transferred to the center of the mold and
oriented in a way that the face down tissue will be the cutting side.
5. The molten paraffin was dispensed in the mold.
6. As a support, the labeled tissue cassette was added to the top of the mold.
7. The molten paraffin was dispensed in the mold; to cover the face of the plastic
cassette.
8. The mold was placed on a cold plate at – 4°C for 30 minutes.
9. The paraffin block was popped out of the metal mold.
Those paraffin blocks can be stored at room temperature for an infinite time.
2.3.6 Sectioning of the Paraffin-Embedded Tissues
Once the paraffin blocks were made, sectioning and placing them on gelatincoated microscopic slides were essential for staining them. The followings are the
steps that have been used for sectioning the paraffin blocks:1. The station for sectioning was prepared by filling the water bath with distilled
water, turning on the water bath and setting the temperature at 45°C, turning
on the slide warmer and setting the temperature at 75°C, bringing a 25 ml glass
breaker and placing on top of it a regular microscopic slide, making 30%
ethanol and pouring it in a 300 ml plastic squeezing bottle, bringing a forceps,
paintbrush, pencil, blades, a bucket filled with ice cubes, slide box and gelatin-
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coated microscopic slides.
2. The paraffin block was placed face down on the ice cubes for 10 minutes.
3. A fresh blade was inserted in the microtome blade holder.
4. The paraffin block was inserted in the microtome block holder, and aligned in
a way that the blade can create vertical planes of paraffin sections from the
paraffin block.
5. The section thickness was set to 20 µm; to remove the extra paraffin to expose
the tissue embedded inside it. Rotating the drive wheel was started to make the
paraffin sections.
6. The paintbrush was used to remove the paraffin sections that don't contain the
tissue out of the way.
7. The section thickness was changed to 5 µm, once the cutting came near to the
tissue.
8. The forceps were used to pick up the paraffin sections that contain the tissue.
9. The paraffin sections were placed on the regular microscopic slide, and added
to the few drops of 30% ethanol; to stretch them.
10. The sections were transferred to the water bath.
11. The gelatin-coated microscopic slides were used to pick up the floating
sections from the water bath.
12. The pencil was used to label the gelatin-coated microscopic slides.
13. The labeled gelatin-coated microscopic slides that contain the sections were
placed on the slide warmer for 10 minutes. This step was done to make sure
that the tissue will bind to the slide.
14. The slides were stored in the slide box at room temperature for an infinite time.
Those slides now can be used for staining.
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2.4 Hematoxylin & Eosin [H&E] Staining
This kind of staining contains a basic dye, which is the hematoxylin, and an
acidic dye, which is the eosin (Batra, 2018). The hematoxylin is a combination of
hematein and a mordant, which is the aluminum salts (Batra, 2018). The mordant binds
to basophilic or acidic structures of the tissue, then the hematein binds to the mordant,
making a tissue-mordant-hematein linkage, and that is the hematoxylin dye (Batra,
2018). This dye stains the structures as purplish-blue (Batra, 2018). On the other hand,
the eosin binds to acidophilic or basic structures of the tissue, which stains them
pinkish-red (Batra, 2018). The acidic structures are the anionic components of a cell,
such as the nucleic acids that are basophilic, which will react with the basic dyes
(Batra, 2018). The basic structures are the cationic components of a cell, like the
cytoplasmic proteins that are acidophilic, which will react with the acidic dyes (Batra,
2018).
In this study, an H&E stain was used to visualize the internal structure of the
bone. The sections were made from two groups, three animals in each group. From
each animal, 10 -15 sections of 5 μm thickness, were made using a microtome.
The sections were stained with H&E, as described below:1. The slides containing the paraffin sections were incubated at 60°C for 15
minutes.
2. 100% Xylene-I [Dewaxing] = 3 minutes.
3. 100% Xylene-II [Dewaxing]= 3 minutes.
4. 100% Ethanol-I [Hydration] = 3 minutes.
5. 100% Ethanol-II [Hydration] = 3 minutes.
6. 95% Ethanol [Hydration] = 3 minutes.
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7. 90% Ethanol [Hydration] = 3 minutes.
8. 70% Ethanol [Hydration] = 3 minutes.
9. 50% Ethanol [Hydration] = 3 minutes.
10. Distilled water-I = 5 minutes.
11. Distilled water-II = 5 minutes.
12. Distilled water-III = 5 minutes.
13. Encircle the tissue on the slide with a pap pen.
14. Mayer’s Hematoxylin [mix A and B equal volumes = 100 μL / tissue] = 8
minutes.
15. Tap water wash = 10 minutes.
16. Distilled water wash = Rinse.
17. 95% Ethanol = 10 Dips.
18. Eosin Y [100 μL / tissue] = 30 Seconds.
19. 70% Ethanol [Dehydration] = 5 minutes.
20. 95% Ethanol [Dehydration] = 5 minutes.
21. 100% Ethanol-I [Dehydration] = 5 minutes.
22. 100% Ethanol-II [Dehydration] = 5 minutes.
23. 100% Xylene-I [Clearing] = 5 minutes.
24. 100% Xylene-II [Clearing] = 5 minutes.
25. The stained sections were mounted using DPX; to adhere to the coverslip to
the slide.
26. The stained sections were visualized under a brightfield microscope.
2.5 Masson's Trichrome Staining
The principle of this stain is that the paraffin sections will be fixed by Bouin's
solution, which will act as a retrieval of the binding sites for acidic dyes (Mokobi,
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2020). The hematoxylin is a basic dye, which is a combination of hematein and
aluminum salts that acts as a mordant (Mokobi, 2020). This mordant binds to the acidic
structures of the tissue, then allowing the hematein to bind to it, creating a linkage of
tissue-mordant-hematein, and that gives the acidic structures, which are the nuclei, its
color as black or dark purple (Mokobi, 2020). The acid fuchsin is an acidic red dye
that will stain the cytoplasm, which is a basic structure, red (Mokobi, 2020). The
phosphomolybdic-phosphotungstic acid solution will specifically remove the red dye
from the collagen (Mokobi, 2020). Aniline blue will stain all the structures that are no
longer bound to the red dye, which is the collagen, as blue (Mokobi, 2020). Finally,
acetic acid will remove the unbound aniline blue from the tissue section (Mokobi,
2020).
In this study, Masson's Trichrome stain was used to measure the trabecular
measurements, which are consisting of trabecular bone volume (BV/TV), trabecular
separation (Tb. Sp), trabecular thickness (Tb. Th), and trabecular number (Tb. N).
Staining interpretation:
Collagen → blue
Muscle fibers → red
Nuclei → dark red to black/blue
Reagents used:1. Bouin’s solution.
2. Hematoxylin (A+B = Equally).
3. Acid fuchsin.
4. Aniline blue.

35
5. Phosphomolybdic-Phosphotungstic Acid Solution (Equal parts of the two acids
+ Distilled water = Equally).
6. 1% Acetic acid (100 μL of Acetic acid + 10 ml of Distilled Water).
The sections were made from two groups, three animals in each group. From
each animal, 10 -15 sections of 5 μm thickness, were made using a microtome.
Protocol for Masson's Trichrome staining:1. The slides containing the paraffin sections were incubated at 60°C for 15
minutes.
2. 100% Xylene-I [Dewaxing] = 5 minutes.
3. 100% Xylene-II [Dewaxing] = 5 minutes.
4. 100% Ethanol-I [Hydration] = 5 minutes.
5. 100% Ethanol-II [Hydration] = 5 minutes.
6. 95% Ethanol [Hydration] = 3 minutes.
7. 90% Ethanol [Hydration] = 3 minutes.
8. 70% Ethanol [Hydration] = 3 minutes.
9. 50% Ethanol [Hydration] = 3 minutes.
10. Distilled Water-I = 5 minutes.
11. Distilled Water-II = 5 minutes.
12. Distilled Water-III = 5 minutes.
13. Oven the Bouin’s solution at 56°C.
14. Preheated Bouin’s solution = 60 minutes.
15. Tap water cooling = 30 minutes.
16. Wash in tap water until the yellow color is removed.
17. Hematoxylin = 20 minutes.
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18. Running tap water = 10 minutes.
19. Rinse in Distilled water.
20. Acid Fuchsin = 20 minutes.
21. Rinse in Distilled water.
22. Phosphomolybdic-Phosphotungstic Acid Solution = 20 minutes.
23. Aniline blue = 20 minutes.
24. Acetic acid (1%) = 8 minutes.
25. Rinse in Distilled water.
26. 95% Ethanol [Dehydration] = 1 minute.
27. 100% Ethanol-I [Dehydration] = 2 minutes.
28. 100% Ethanol-II [Dehydration] = 2 minutes.
29. 100% Xylene-I [Clearing] = 10 minutes.
30. 100% Xylene-II [Clearing] = 10 minutes.
31. The stained sections were mounted using DPX; to adhere the coverslip to the
slide.
32. The stained sections were visualized under a brightfield microscope.
2.6 TUNEL [Terminal deoxynucleotidyl transferase dUTP Nick End Labeling]
Assay
The TUNEL staining was used to detect apoptotic nuclei in paraffin-embedded
tissue sections (Gao et al., 2017). One of the biochemical hallmarks of apoptosis is the
generation of free 3′-hydroxyl termini on DNA via cleavage of chromatin into single
and multiple oligonucleosome-length fragments (Gao et al., 2017). The TdT-mediated
dUTP-biotin nick end labeling (TUNEL) assay exploits this biochemical hallmark by
labeling the exposed termini of DNA, thereby enabling visualization of nuclei
containing fragmented DNA (Gao et al., 2017). Apoptosis was measured using
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TUNEL Assay Kit - HRP-DAB (ab206386). In response to apoptotic signals, the assay
uses Terminal deoxynucleotidyl Transferase (TdT) that will bind to the exposed 3’OH ends of DNA fragments and catalyzes the addition of biotin-labeled
deoxynucleotides. Then, the Streptavidin-Horseradish Peroxidase (HRP) conjugate
detects the biotinylated nucleotides. After that, those HRP-labeled samples got reacted
with diaminobenzidine (DAB) and stains those cells as dark brown.
Reagents used:1. 1x TBS [Tris-buffered Saline] (6.05 g of 50 mM Tris and 8.76 g of 150 NaCl
were dissolved in 800 ml dH2O, the pH was adjusted to 7.6 with 1M HCl, then
made up the volume to 1L with dH2O).
2. PAP pen.
3. Proteinase K.
4. 30% H2O2.
5. TdT Equilibration Buffer.
6. TdT enzyme.
7. TdT Labeling Reaction Mix.
8. Stop Buffer.
9. Blocking Buffer.
10. 25x Conjugate.
11. DAB Solution 1.
12. DAB Solution 2.
13. Methyl Green Counterstain solution.
The sections were made from two groups, three animals in each group. From
each animal, 10 -15 sections of 5 μm thickness, were made using a microtome.
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The protocol for TUNEL Assay Kit - HRP-DAB (ab206386) according to the
manufacturer’s instructions with some modification:Briefly, the paraffin sections were rehydrated and permeabilized with
Proteinase K at room temperature for 20 minutes. Endogenous peroxidases were
inactivated by 3% H2O2 at room temperature for 15 minutes. TdT Equilibration Buffer
was added to sections for equilibration and incubated at room temperature for 30
minutes. The sections were labeled by TdT Labeling Reaction Mixture and incubated
in a humidified chamber at 37°C for 1.5 hours. The Stop buffer was added and
incubated at room temperature for 5 minutes; to terminate the labeling reaction.
Blocking Buffer was added and incubated at room temperature for 10 minutes.
Following the addition of 25x Conjugate and incubation in a humidified chamber at
room temperature for 30 minutes; for detection. The sections were developed by DAB
solution and counterstained by the Methyl Green Counterstain solution.
The following steps described the procedure that was performed for the slides
containing the paraffin sections:
2.6.1 Rehydration
1. 100% Xylene-I = 5 minutes.
2. 100% Xylene-II = 5 minutes.
3. 100% Ethanol-I = 5 minutes.
4. 100% Ethanol-II = 5 minutes.
5. 90% Ethanol = 3 minutes.
6. 80% Ethanol = 3 minutes.
7. 70% Ethanol = 3 minutes.
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8. 1x TBS = 5 minutes.
9. The glass slide around the paraffin-embedded tissue section was dried, and
encircled using a PAP pen.
2.6.2 Permeabilization of Specimen
1. For each section, 100 µl of the diluted Proteinase [1:100 dilution, 1 μL of
Proteinase K + 99 μL of dH2O] was added. Then, incubated at room
temperature for 20 minutes.
2. 1x TBS = 5 minutes.
3. The glass slide around the paraffin-embedded tissue section was dried.
2.6.3 Quenching: Inactivation of Endogenous Peroxidases
1. For each section, 100 µl of 3% H2O2 [1:10 dilution, 10 μL of 30% H2O2 + 90
μL of methanol] was added. Then, incubated at room temperature for 15
minutes.
2. 1x TBS = 5 minutes.
3. The glass slide around the paraffin-embedded tissue section was dried.
2.6.4 Equilibration
1. For each section, 100 µl of TdT Equilibration Buffer was added. Then,
incubated at room temperature for 30 minutes.
2. At 25 minutes of incubation, the next step proceeded.
2.6.5 Labeling Reaction
1. Before opening the TdT enzyme tube, the TdT enzyme tube was pulse spined.
2. In an Eppendorf tube, the working TdT Labeling Reaction Mixture was
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prepared by adding 1 µl of TdT enzyme and adding 39 µl of TdT Labeling
Reaction Mix [this is only for one section, the calculation was done according
to the number of sections]. It was gently mixed and kept on ice until use.
3. The TdT Equilibration Buffer was blotted from the section.
4. For each section, 40 µl of the working TdT Labeling Reaction Mixture was
added.
5. The sections were covered with coverslips; to avoid evaporation during
incubation.
6. The sections were incubated in a humidified chamber at 37°C for 1.5 hours.
2.6.6 Termination of the Labeling Reaction
1. The Stop Buffer was warmed to 37°C for 5 minutes.
2. The coverslips were removed from the sections.
3. 1x TBS = 5 minutes.
4. For each section, 100 µl of the Stop Buffer was added and incubated at room
temperature for 5 minutes.
5. 1x TBS = 5 minutes.
6. The glass slide around the paraffin-embedded tissue section was dried.
2.6.7 Blocking
1. For each section, 100 µl of the Blocking Buffer was added. Then, incubated at
room temperature for 10 minutes.
2. At 5 minutes of incubation, the next step was proceeded.
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2.6.8 Detection
1. In an Eppendorf tube, the 25x Conjugate (1:25 dilution) was diluted by adding
4 µl of 25x Conjugate and adding 96 µl of the Blocking Buffer [this is only for
one section, the calculation was done according to the number of sections]. It
was gently mixed and kept on ice until use.
2. The Blocking Buffer was blotted from the section.
3. For each section, 100 µl of the diluted 25x Conjugate was added.
4. The sections were incubated in a humidified chamber at room temperature for
30 minutes.
5. 1x TBS = 5 minutes.
2.6.9 Development
1. The glass slide around the paraffin-embedded tissue section was dried.
2. In an Eppendorf tube, prepare the working DAB solution (1:30 dilution) was
prepared by adding 4 µl of DAB Solution 1 and adding 116 µl of DAB Solution
2 [this is only for one section, the calculation was done according to the number
of sections]. It was gently mixed and kept on ice until use.
3. For each section, 100 µl of the working DAB solution was added.
4. The sections were incubated at room temperature for 15 minutes.
5. Rinse in distilled water.
2.6.10 Counterstain
1. For each section, 100 µl of Methyl Green Counterstain solution was added.
2. The sections were incubated at room temperature for 3 minutes.
3. The counterstain was drawn off from the slide against an absorbent towel.
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4. 100% Ethanol-I = Dip 4 times.
5. The slide was blotted on an absorbent towel.
6. 100% Ethanol-II = Dip 4 times.
7. The slide was blotted on an absorbent towel.
8. 100% Xylene = Dip 4 times.
9. The stained sections were mounted using DPX; to adhere to the coverslip to
the slide.
10. The stained sections were visualized under a brightfield microscope.
2.7 Molecular Biology Experiments
2.7.1 RNA Extraction from Bones
The mirVanaTM miRNA Isolation Kit (Invitrogen by Thermo Fisher
Scientific) was used to purify the total RNA containing the microRNAs from the shaft
of the tibia of the control and T2DM groups. This isolation kit relies on the advantage
of combing two methods of isolation: chemical extraction [inactivate Rnases and very
pure preparations of RNA] and solid-phase extraction [decrease the affinity of RNA
for water and increase its affinity for the solid support], which is producing high yields
of ultra-pure and high-quality RNA molecules.
Reagents used:1. miRNA Wash Solution 1 [for the first time use, add 21 ml of 100% ethanol to
it before use].
2. Wash Solution 2/3 [for the first time use, add 40 ml of 100% ethanol before
use].
3. Acid-Phenol: Chloroform.
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4. Lysis/Binding Buffer.
5. miRNA Homogenate Additive.
6. Elution Solution [nuclease-free 0.1 mM EDTA].
7. Collection tubes.
8. Filter Cartridges.
The protocol for miVana miRNA Isolation Kit according to the manufacturer’s
instructions:1. Bone samples were crushed into powder using the mortar and pestle with liquid
nitrogen.
2. In an Eppendorf tube, the powdered bone was collected, and added 600 µl of
Lysis/Binding Buffer to it and mixed rapidly.
3. To the same Eppendorf tube, 1/10 volume of miRNA Homogenate Additive
[60 µl] was added. The tube was vortexed to mix well.
4. The tube was incubated on ice for 10 minutes.
5. To the same tube, 600 µl of Acid-Phenol: Chloroform was added [the volume
of Acid-Phenol: Chloroform should be equal to the lysate volume before the
addition of the miRNA Homogenate Additive].
6. Mixed by vortexing for 60 seconds.
7. Centrifuged at 10,000 rpm at room temperature for 5 minutes.
8. Without disturbing the lower phase, remove the upper phase was removed and
transferred to a fresh tube. Record the volume of the removed upper phase was
recorded.
9. The Elution Solution was preheated to 95°C.
10. 1.25 volumes of 100% ethanol were added to the removed upper phase [if the
volume of the removed upper phase was 300 µl, 375 µl of 100% ethanol will
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be added].
11. A collection tube was brought and placed a filter cartridge into it.
12. The lysate/ethanol mixture was added onto the filter cartridge [the addition of
the mixture should be no more than 700 µl, and if the volume of the mixture
was more than 700 µl, the mixture in successive applications will be applied to
the same filter].
13. Centrifuged at 10,000 rpm at room temperature for 15 seconds; to let the
mixture pass through the filter.
14. The flow-through was discarded from the collection tube. The same filter
cartridge was placed into the same collection tube.
15. 700 µl of miRNA Wash Solution 1 was added onto the filter cartridge.
16. Centrifuged at 10,000 rpm at room temperature for 10 seconds; to let the
miRNA Wash Solution 1 pass through the filter.
17. The flow-through was discarded from the Collection tube. The same filter
cartridge was placed into the same collection tube.
18. 500 µl of Wash Solution 2/3 was added onto the filter cartridge.
19. Centrifuged at 10,000 rpm at room temperature for 10 seconds; to let the Wash
Solution 2/3 pass through the filter.
20. The flow-through was discarded from the Collection tube. The same filter
cartridge was placed into the same collection tube.
21. 500 µl of Wash Solution 2/3 was added onto the filter cartridge.
22. Centrifuged at 10,000 rpm at room temperature for 10 seconds; to let the Wash
Solution 2/3 will through the filter.
23. The flow-through was discarded from the collection tube. The same filter
cartridge was placed into the same collection tube.
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24. To remove residual fluid from the filter, the assembly was spined for 1 minute.
25. The collection tube was discarded, and a new collection tube was brought and
the same filter cartridge was placed into it.
26. 25 µl of the preheated Elution Solution was added to the filter cartridge.
27. Centrifuged at 14,000 rpm at room temperature for 30 seconds; to let the
Elution Solution containing the RNA pass through the filter.
28. Another 25 µl of the preheated Elution Solution was added to the filter
cartridge.
29. Centrifuged at 14,000 rpm at room temperature for 30 seconds; to let the
Elution Solution containing the RNA pass through the filter.
30. The filter cartridge was discarded.
31. The collection tube that has the eluate, which contains the total RNA along
with the microRNAs was stored at –80°C. The concentration of the total RNA
(ng/µl) was measured by the NanoDrop 2000 spectrophotometer from Thermo
Fisher Scientific.
2.7.2 RNA Extraction from Serum
The total RNA from the sera of the control and T2DM groups were isolated by
performing the following steps:
1. The serum was centrifuged at 3000 rpm at 4°C for 10 minutes.
2. In an Eppendorf tube, the serum supernatant was transferred to it.
3. In the same Eppendorf tube, 1/10 volume of miRNA Homogenate Additive
was added and mixed well.
4. The tube was incubated on ice for 10 minutes.
5. 3.0 volumes of Acid-Phenol: Chloroform was added.
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6. Mixed by inverting it several times.
7. Centrifuged at 16,000 rpm at 4°C for 10 minutes.
8. Without disturbing the lower phase, the upper phase was removed and
transferred to a fresh tube. The volume of the removed upper phase was
recorded.
9. Equal to or more than the volume of the removed upper phase, the isopropanol
was added.
10. Mixed by inverting it several times.
11. Centrifuged at 16,000 rpm at 4°C for 15 minutes.
12. The supernatant was removed by inverting it up-side-down.
13. To the same tube, 500 µl of the washing solution was added [35 ml of 70%
ethanol + 15 ml of nuclease-free water].
14. Mixed by inverting it several times.
15. Centrifuged at 16,000 rpm at 4°C for 5 minutes.
16. The supernatant was removed by inverting it up-side-down.
17. The tube was centrifuged briefly and the supernatant was removed by using the
pipette.
18. The pellet was resuspended in 20 µl of nuclease-free water.
19. The tube that has the total RNA along with the microRNAs was stored at –
80°C. The concentration of the total RNA (ng/µl) was measured by the
NanoDrop 2000 spectrophotometer from Thermo Fisher Scientific.
2.8 Reverse Transcription
2.8.1 For the MicroRNAs
For reverse transcription, the TaqMan® Small RNA Assays (Applied
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Biosystems by Thermo Fisher Scientific) was used to reverse transcribe cDNA from
total RNA. The steps below were followed according to the manufacturer’s
instructions with some modification; to perform the reverse transcription:
1. The following components of the reverse transcription kit were thawed on ice:
a. 100mM dNTPs (with dTTP).
b. 10x Reverse Transcription Buffer.
c. RNase Inhibitor, 20 U/µl.
2. The following RT primers were thawed on ice:
d. miR-20a (Assay ID: 001336).
e. miR-21 (Assay ID: 000397).
f. miR-29a (Assay ID: 002447).
g. miR-31 (Assay ID: 002495).
h. miR-155 (Assay ID 002571).
i. U6 snRNA [as an internal control for the microRNAs] (Assay ID:
001973).
3. For one reaction, 0.15 µl of 100mM dNTPs (with dTTP) + 1.50 µl of 10x
Reverse Transcription Buffer + 4.16 µl of nuclease-free water + 0.19 µl of
RNase Inhibitor, 20 U/µl + 1.00 µl of MultiScribeTM Reverse Transcriptase, 50
U/µl, were added to a microcentrifuge tube.
4. Mixed by inversion, and briefly centrifuged.
5. To the same microcentrifuge tube that contains the RT Reaction Mix, 3 µl of
one of the RT primers was added. Note that for the other RT primers, each one
should have its microcentrifuge tube containing the RT Reaction Mix.
6. According to the concentration of the sample, The volume (µl) that should be
added to the same microcentrifuge tube that contains the RT Reaction Mix was
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calculated (0.5 µg of the total RNA from the bones and 1 µg of the total RNA
from the sera).
7. The total volume of the reaction was made up to 20 µl by the addition of
nuclease-free water.
8. The reaction tube was briefly centrifuged.
9. The reaction tube was placed into the thermal cycler, and performed the
standard cycling steps as follows:
j. First reverse transcription at 16°C for 30 minutes.
k. Second reverse transcription at 42°C for 30 minutes.
l. Reaction was stopped at 85°C for 5 minutes.
m. Lastly, hold at 4°C.
10. The product of the reverse transcription was stored at –20°C.
2.8.2 For the Target Genes of the MicroRNAs
For reverse transcription, the High-Capacity cDNA Reverse Transcription Kits
(Applied Biosystems by Thermo Fisher Scientific) was used to reverse transcribe
cDNA from total RNA. The steps below were followed according to the
manufacturer’s instructions with some modifications; to perform the reverse
transcription:
1. The following components of the reverse transcription kit were thawed on ice:
a. 10x RT Buffer.
b. 25x dNTP Mix [100 mM].
c. 10x RT Random Primers.
d. RNase Inhibitor, 20 U/µl.
2. For one reaction, 0.8 µl of 25x dNTP Mix [100 mM] + 2.0 µl of 10x RT Buffer
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+ 3. 2 µl of nuclease-free water + 2.0 µl of 10x RT Random Primers + 1.0 µl
of RNase Inhibitor, 20 U/µl + 1.0 µl of MultiScribeTM Reverse Transcriptase,
50 U/µl, was added to a microcentrifuge tube.
3. Mixed by inversion and briefly centrifuged.
4. According to the concentration of the sample, the volume (µl) that should be
added to the same microcentrifuge tube that contains the RT Master Mix was
calculated (1 µg of the total RNA from the bones).
5. The total volume of the reaction was made up to 20 µl by the addition of
nuclease-free water.
6. The reaction tube was briefly centrifuged.
7. The reaction tube was placed into the thermal cycler, and performed the
standard cycling steps as follows:
a. First step at 25°C for 10 minutes.
b. Second step at 37°C for 120 minutes.
c. Third step at 85°C for 5 minutes.
d. Lastly, hold at 4°C.
8. The product of the reverse transcription was stored at –20°C.
2.9 Quantification Real-Time PCR
For quantification-Real Time PCR, the TaqMan® Small RNA Assays (Applied
Biosystems by Thermo Fisher Scientific) was used to amplify the cDNA. The steps
below were followed according to the manufacturer’s instructions with some
modifications; to perform the quantification-Real Time PCR:
1. The following primers were thawed on ice:
a. miR-20a (Assay ID: 001336).
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b. miR-21 (Assay ID: 000397).
c. miR-29a (Assay ID: 002447).
d. miR-31 (Assay ID: 002495).
e. miR-155 (Assay ID 002571).
f. U6 snRNA [as an internal control for the microRNAs] (Assay ID:
001973).
g. ACTB [Actin-Beta, as an internal control for the target genes of the
microRNAs] (Assay ID: Rn00667869_m1).
h. ATG16L1

[Autophagy

Related

16

Like

1]

(Assay

ID:

Rn01400301_m1).
i. BAMBI [Bone Morphogenetic Protein and Activin Membrane-Bound
Inhibitor] (Assay ID: Rn00594597_m1).
j. BMP2 [Bone Morphogenetic Protein 2] (Assay ID: Rn00567818_m1).
k. BMP3 [Bone Morphogenetic Protein 3] (Assay ID: Rn00567346_m1).
l. CALCA [Calcitonin Related Polypeptide Alpha] (Assay ID:
Rn00569199_m1).
m. CRIM1 [Cysteine rich transmembrane BMP regulator 1] (Assay ID:
Rn01232943_m1).
n. DKK1 [Dickkopf WNT Signaling Pathway Inhibitor 1] (Assay ID:
Rn01501537_m1).
o. KREMEN2 [Kringle Containing Transmembrane Protein 2] (Assay ID:
Rn01752365_m1).
p. MITF [Microphthalmia-associated transcription factor] (Assay ID:
Rn01425766_m1).
q. PDCD4

[Programmed

cell

death

protein

4]

(Assay

ID:
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Rn00573954_m1).
r. PPARG [Peroxisome proliferator activated receptor gamma] (Assay
ID: Rn00440945_m1).
s. RhoA [Ras homolog family member A] (Assay ID: Rn00589172_m1).
t. RUNX2 [Runt-related transcription factor 2 (CBFA1)] (Assay ID:
Rn01512298_m1).
u. SATB2 [Special AT-Rich Sequence-Binding Protein 2] (Assay ID:
Rn01438160_m1).
v. SFRP2

[Secreted

frizzled-related

protein

2]

(Assay

ID:

Rn01458837_m1).
w. SMAD7 [Caenorhabditis elegans SMA ("small" worm phenotype) and
Drosophila MAD ("Mothers Against Decapentaplegic") (Smad family
member 7)] (Assay ID: Rn00578319_m1).
x. SOCS1 [Suppressor of cytokine signaling 1 (STAT-induced STAT
inhibitor 1 (SSI))] (Assay ID: Rn00595838_s1).
y. SOST [Sclerostin] (Assay ID: Rn00577971_m1).
z. SP7

[Sp7

Transcription

Factor

(Osterix)]

(Assay

ID:

Rn01761789_m1).
aa. SRF [Serum Response Factor] (Assay ID: Rn01757240_m1).
bb. TGFB1

[Transforming Growth Factor

Beta 1]

(Assay ID:

Rn00572010_m1).
cc. TNFRSF11B [Tumor necrosis factor receptor superfamily member 11b
(OPG)] (Assay ID: Rn00563499_m1).
dd. TNFSF11 [Tumor Necrosis Factor Ligand Superfamily Member 11
(RANKL)] (Assay ID: Rn00589289_m1).
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2. In a microcentrifuge tube, PCR Reaction Mix was prepared by adding 7 µl of
nuclease-free water, 10 µl of PCR Master Mix, and 1 µl of one of the primers.
Note that for the other primers, each one should have its microcentrifuge tube
containing the PCR Reaction Mix.
3. 1 µl of the cDNA was added, if the reaction was meant for determining
microRNAs. 2 µl of the cDNA was added, if the reaction is meant for
determining the target genes of the microRNAs.
4. The reaction tube was briefly centrifuged.
5. The reaction tube was placed into the QuantStudioTM 7 Flex Real-Time PCR
system (Applied Biosystems by Thermo Fisher Scientific), and programed the
thermal-cycling conditions as follows for 50 cycles:
ee. UNG activation at 50°C for 2 minutes.
ff. Enzyme activation at 94°C for 10 minutes.
gg. Denature at 95°C for 15 seconds.
hh. Anneal/Extend at 60°C for 60 seconds.
The expression analysis, using TaqMan® Small RNA Assays, was performed using
the comparative delta-delta Ct method. The internal controls used for the normalization
of microRNAs was U6 snRNA and for target mRNAs was Actin-Beta. Each
experiment was performed in duplicates and repeated three times.
2.10 Enzyme-linked Immunosorbent Assay [ELISA] Kit For Osteocalcin [OC]
The ELISA kit for osteocalcin (Cloud-Clone Corp. / SEA471Ra) is a
quantitative measurement and a type of a sandwich enzyme immunoassay. The kit’s
microplate wells are coated with a biotin-conjugated antibody that is specific to
osteocalcin. To each well, the serum samples are added along with Avidin that is
conjugated to Horseradish Peroxidase (HRP). The TMB substrate solution is added
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afterward. The wells that exhibit a change in color (blue) are the ones that contain
osteocalcin, and it is measured (referring to the optical density of osteocalcin)
spectrophotometrically at a wavelength of 450 nm.
Reagents used, which were supplied by the company in the kit:1. Standard and Standard Diluent.
2. Detection Reagent A and Assay Diluent A.
3. Detection Reagent B and Assay Diluent B.
4. TMB substrate and Stop solution.
5. 1x Wash solution.
6. Pre-coated 96-well strip plate and plate sealer.
The protocol for measuring osteocalcin in sera using ELISA kit (Cloud-Clone Corp. /
SEA471Ra) was done according to the manufacturer’s instructions:1. The following components of the ELISA kit were brought to room
temperature:
a. Serum samples of the control and T2DM groups.
b. Standard and Standard Diluent.
c. Detection Reagent A and Assay Diluent A.
d. Detection Reagent B and Assay Diluent B.
e. TMB substrate and Stop solution.
f. 1x Wash solution.
2. 1 ml of Standard Diluent was added to the Standard, inverted gently, and kept
for 10 minutes at room temperature.
3. The concentration of the Standard is 5000 pg/ml. 7 points of diluted standard
were made as 1000 pg/ml, 500 pg/ml, 250 pg/ml, 125 pg/ml, 62.5 pg/ml, 31.2
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pg/ml and 15.6 pg/ml.
4. The blank was made as 0 pg/ml by adding only the Standard Diluent.
5. A 100 fold dilution was made of Detection Reagent A with Assay Diluent A
and Detection Reagent B with Assay Diluent B.
6. On the pre-coated 96-well strip plate, the wells were defined for the 7 diluted
standards, the blank, and the serum samples.
7. 100 μl of the diluted standards, the blank, and the serum samples were added
into their defined wells.
8. The wells were covered with a plate sealer and incubated for 1 hour at 37°C.
9. The content of each well was removed.
10. 100 μl of Detection Reagent A was added into each well.
11. The wells were covered with a plate sealer and incubated for 1 hour at 37°C.
12. The content of each well was removed.
13. 350 μl of 1x Wash solution was added into each well and stood for 2 minutes.
14. The content of each well was removed.
15. Step 13 and step 14 were performed three times.
16. 100 μl of Detection Reagent B was added into each well.
17. The wells were covered with a plate sealer and incubated for 30 minutes at
37°C.
18. Step 13 and step 14 were performed five times.
19. 90 μl of TMB substrate solution was added into each well.
20. The wells were covered with a new plate sealer and incubated for 20 minutes
at 37°C in dark.
21. 50 μl of Stop solution was added into each well, mixed by tapping the side of
the plate.
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22. Bubbles were inspected and removed.
23. The bottom of the plate was cleaned.
24. The absorbance (optical density) was read at 450 nm wavelength for the diluted
standards, the blank, and the serum samples by using the spectrophotometer.
25. The calibration curve was created; to measure the osteocalcin concentration of
the samples.
2.11 Rat Osteocalcin ELISA Kit
The Rat Osteocalcin ELISA kit (Abbkine / KTE101053) is a quantitative
measurement and a type of a sandwich enzyme immunoassay. The kit’s microplate
wells are coated with an immobilized antibody that is specific to osteocalcin. To each
well, the bone samples [bone hydrolysate] are added along with Rat Osteocalcin
detection antibody that is conjugated to Horseradish Peroxidase (HRP). The
Chromogen solution is added afterward. The wells that exhibit a change in color
(yellow) are the ones that contain osteocalcin, and it is measured (referring to the
optical density of osteocalcin) spectrophotometrically at a wavelength of 450 nm.
Reagents used, which were supplied by the company in the kit:1. Standard diluent.
2. Sample diluent.
3. Chromogen solution A.
4. Chromogen solution B.
5. Stop solution.
6. 1x Wash Buffer.
7. Pre-coated 96-well Rat Osteocalcin microplate.
8. Plate covers.
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9. Rat Osteocalcin standard.
10. HRP-Conjugated Rat Osteocalcin detection antibody.
Sample preparation:
The bones were cleaned and washed in 1x PBS. Then, dried on tissue paper and ground
with liquid nitrogen. 10 volume of 2 M acetic acid was added to each of the bone
powder. Boiled for 10 minutes. Centrifuged at 3000 g for 15 minutes. Lastly, the
supernatant was taken from each sample and transferred to their labeled Eppendorf
tubes. The bone hydrolysates were formed by the Acid-Resistant CentriVap
Concentrator from LABCONCO and added 10 μl of PBS to the sample.
The protocol for measuring osteocalcin in bones using Rat Osteocalcin ELISA kit
(Abbkine / KTE101053) was done according to the manufacturer’s instructions:1. The following components of the ELISA kit were brought to room
temperature:
a. Bone hydrolysate samples of the control and T2DM groups.
b. Standard diluent.
c. Sample diluent.
d. Chromogen solution A.
e. Chromogen solution B.
f. Stop solution.
g. 1x Wash buffer.
h. Rat Osteocalcin standard.
2. 150 μl of Standard Diluent was added to the Rat Osteocalcin standard, inverted
gently.
3. The concentration of the Standard is 1600 ng/l. 5 points of diluted standard
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were made (2-fold dilution) as 800 ng/l, 400 ng/l, 200 ng/l, 100 ng/l, 50 ng/l.
4. The blank was made as 0 pg/ml by adding only the Standard Diluent.
5. On the pre-coated 96-well strip plate, the wells were defined for the 5 diluted
standards, the blank, and the bone hydrolysate samples.
6. 50 μl of the diluted standards were added into their defined wells.
7. 40 μl of sample diluent and 10 μl of bone hydrolysate samples were added into
their defined wells.
8. The wells were covered with a plate cover and incubated for 45 minutes at
37°C.
9. The content of each well was removed.
10. 250 μl of 1x Wash solution was added into each well and stood for 2 minutes.
11. The content of each well was removed.
12. Step 10 and step 11 were performed five times.
13. 50 μl of HRP-Conjugated detection antibody was added to the wells of the 5
diluted standards and the bone hydrolysate samples.
14. The wells were covered with plate cover and incubated for 30 minutes at 37°C.
15. The content of each well was removed.
16. 250 μl of 1x Wash solution was added into each well and stood for 2 minutes.
17. The content of each well was removed.
18. Step 16 and step 17 were performed five times.
19. 50 μl of chromogen solution A and 50 μl of chromogen solution B were added
into each well and mixed gently.
20. The wells were incubated for 15 minutes at 37°C in dark.
21. 50 μl of Stop solution was added into each well, mixed by tapping the side of
the plate.
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22. Bubbles were inspected and removed.
23. The bottom of the plate was cleaned.
24. The absorbance (optical density) was read at 450 nm wavelength for the diluted
standards, the blank, and the bone samples by using the spectrophotometer.
25. The calibration curve was created; to measure the osteocalcin concentration of
the samples.
2.12 Statistical Analysis
The data obtained from quantification Real-Time PCR were presented as mean
relative expression and Standard Error of Mean (SEM), and the p values were achieved
by using Student’s t-test.
The data obtained from ELISA were presented as mean concentration and
Standard Error of Mean (SEM), and the p values were achieved by using Student’s ttest.
The data obtained from the TUNEL assay were presented as mean counts were
achieved by using ImageJ and Standard Error of Mean (SEM), and the p values were
achieved by using Student’s t-test.
The data obtained from Masson’s Trichrome staining were used to measure the
TBV(%) and Tb. Sp (mm) using Image J. The calculation was made for Tb. Th (1/Tb.
Sp) and Tb. N (TBV/Tb. Th). The data were presented as mean measured parameters
[TBV, Tb. Sp, Tb. Th, and Tb. N] and Standard Error of Mean (SEM), and the p values
were achieved by using Student’s t-test.
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Chapter 3: Results
3.1 Identification of MicroRNAs in Bones of 8 Weeks of the Onset of Type 2
Diabetes Mellitus
Five microRNAs were selected to study their expression in the bones of 8
weeks of the onset of type 2 diabetes mellitus, and those microRNAs were miR-20a,
miR-21, miR-29a, miR-31, and miR-155. Quantification Real-Time PCR was
performed to analyze their expression using the comparative delta-delta Ct method.
U6 snRNA was used as an internal control for normalization. Each experiment was
performed in duplicates and repeated three times. The following observations were
recorded:
The expression of miR-31 and miR-29a were non-significantly increased in the
bones of 8 weeks of the onset of type 2 diabetes mellitus, whereas the expression of
miR-20a has non-significantly decreased in the bones of 8 weeks of the onset of type
2 diabetes mellitus as presented in Figure 3.
MiR-21 expression was non-significantly upregulated in 8 weeks of type 2
diabetic rat bone tissue (Figure 4).
MiR-155 expression was non-significantly downregulated in 8 weeks of type
2 diabetic rat bone tissue (Figure 5).
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Figure 3: Upregulation of miR-31 and miR-29a, and downregulation of miR-20a in 8
weeks type 2 diabetic rat bone tissue.
Total RNA isolated from tibiae bone samples of control (n = 3) and T2DM (n = 3)
rats were analyzed by q-RT PCR to quantify miR-31 (p = 0.1379), miR-29a (p =
0.3990) and miR-20a (p = 0.0614) and normalized against U6 snoRNA to plot the
relative expression of miR-31, miR-29a and miR-20a. Student’s t-test, error bars
indicate Standard Error of Mean (SEM).
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Figure 4: Upregulation of miR-21 in 8 weeks type 2 diabetic rat bone tissue.
Total RNA isolated from tibiae bone samples of control (n = 3) and T2DM (n = 3)
rats were analyzed by q-RT PCR to quantify miR-21 (p = 0.2359) and normalized
against U6 snoRNA to plot the relative expression of miR-21. Student’s t-test, error
bars indicate Standard Error of Mean (SEM).

Figure 5: Downregulation of miR-155 in 8 weeks type 2 diabetic rat bone tissue.
Total RNA isolated from tibiae bone samples of control (n = 3) and T2DM (n = 3)
rats were analyzed by q-RT PCR to quantify miR-155 (p = 0.9126) and normalized
against U6 snoRNA to plot the relative expression of miR-155. Student’s t-test, error
bars indicate Standard Error of Mean (SEM).
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3.2 Identification of MicroRNAs in Bones of 10 Weeks of the Onset of Type 2
Diabetes Mellitus
The expression of miR-20a, miR-21, miR-29a, miR-31, and miR-155 was
further examined in the bones of 10 weeks of the onset of type 2 diabetes mellitus.
Quantification Real-Time PCR was performed to analyze their expression using the
comparative delta-delta Ct method. U6 snRNA was used as an internal control for
normalization. Each experiment was performed in duplicates and repeated three times.
The following observations were recorded:
There was a significant reduction of miR-20a (p < 0.05) expression in 10 weeks
type 2 diabetic rat bone tissue, as displayed in Figure 6.
The expression of miR-31 and miR-29a were non-significantly decreased in
the bones of 10 weeks of the onset of type 2 diabetes mellitus as shown in Figure 6.
MiR-21 (p < 0.05) expression was significantly downregulated in 10 weeks
type 2 diabetic rat bone tissue (Figure 7).
The expression of miR-155 (p < 0.05) expression was significantly declined in
the bones of 10 weeks of the onset of type 2 diabetes mellitus (Figure 8).
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Figure 6: The expression of miR-29a and miR-31 is downregulated, the expression of
miR-20a is significantly downregulated in 10 weeks type 2 diabetic rat bone tissue.
Total RNA isolated from tibiae bone samples of control (n = 3) and T2DM (n = 3)
rats were analyzed by q-RT PCR to quantify miR-20a (p = 0.0416), miR-29a (p =
0.2294), and miR-31 (p = 0.4845) and normalized against U6 snoRNA to plot the
relative expression of miR-20a, miR-29a, and miR-31. (Student’s t-test, error bars
indicate Standard Error of Mean (SEM), * indicates significant differences at p <
0.05).
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Figure 7: The expression of miR-21 is significantly downregulated in 10 weeks type
2 diabetic rat bone tissue.
Total RNA isolated from tibiae bone samples of control (n = 3) and T2DM (n = 3)
rats were analyzed by q-RT PCR to quantify miR-21 (p = 0.0193) and normalized
against U6 snoRNA to plot the relative expression of miR-21. (Student’s t-test, error
bars indicate Standard Error of Mean (SEM), * indicates significant differences at p
< 0.05).

Figure 8: The expression of miR-155 is significantly downregulated in 10 weeks type
2 diabetic rat bone tissue.
Total RNA isolated from tibiae bone samples of control (n = 3) and T2DM (n = 3)
rats were analyzed by q-RT PCR to quantify miR-155 (p = 0.0179) and normalized
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against U6 snoRNA to plot the relative expression of miR-155. (Student’s t-test,
error bars indicate Standard Error of Mean (SEM), * indicates significant differences
at p < 0.05).
3.3 Identification of MicroRNAs in Bones of 14 Weeks of the Onset of Type 2
Diabetes Mellitus
The expression of miR-20a, miR-21, miR-29a, miR-31, and miR-155 was
determined in one more time point. Therefore, their expression have been studied in
the bones of 14 weeks of the onset of type 2 diabetes mellitus. Quantification RealTime PCR was performed to analyze their expression using the comparative deltadelta Ct method. U6 snRNA was used as an internal control for normalization. Each
experiment was performed in duplicates and repeated three times. The following
observations were recorded:
There was non-significant upregulation of miR-20a expression, and nonsignificant downregulation of the expression of miR-29a and miR-31 in 14 weeks type
2 diabetic rat bone tissue, as described in Figure 9.
MiR-21 expression was non-significantly lowered in 14 weeks type 2 diabetic
rat bone tissue (Figure 10).
The expression of miR-155 was non-significantly raised in the bones of 14
weeks of the onset of type 2 diabetes mellitus (Figure 11).
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Figure 9: Upregulation of miR-20a, and downregulation of miR-29a and miR-31 in
14 weeks type 2 diabetic rat bone tissue.
Total RNA isolated from tibiae bone samples of control (n = 3) and T2DM (n = 3)
rats were analyzed by q-RT PCR to quantify miR-20a (p = 0.2709), miR-29a (p =
0.1552), and miR-31 (p = 0.6650) and normalized against U6 snoRNA to plot the
relative expression of miR-20a, miR-29a, and miR-31. Student’s t-test, error bars
indicate Standard Error of Mean (SEM).
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Figure 10: Downregulation of miR-21 in 14 weeks type 2 diabetic rat bone tissue.
Total RNA isolated from tibiae bone samples of control (n = 3) and T2DM (n = 3)
rats were analyzed by q-RT PCR to quantify miR-21 (p = 0.4788) and normalized
against U6 snoRNA to plot the relative expression of miR-21. Student’s t-test, error
bars indicate Standard Error of Mean (SEM).

Figure 11: Upregulation of miR-155 in 14 weeks type 2 diabetic rat bone tissue.
Total RNA isolated from tibiae bone samples of control (n = 3) and T2DM (n = 3)
rats were analyzed by q-RT PCR to quantify miR-155 (p = 0.1220) and normalized
against U6 snoRNA to plot the relative expression of miR-155. Student’s t-test, error
bars indicate Standard Error of Mean (SEM).
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3.4 Identification of MicroRNAs in Sera of 8 Weeks of the Onset of Type 2
Diabetes Mellitus
The expression of miR-20a, miR-21, miR-29a, miR-31, and miR-155 were
further investigated in the sera of 8 weeks of the onset of type 2 diabetes mellitus; to
know whether the results that were founded in the bones can be expressed in the sera
as well. Quantification Real-Time PCR was performed to analyze their expression
using the comparative delta-delta Ct method. U6 snRNA was used as an internal
control for normalization. Each experiment was performed in duplicates and repeated
three times. The following observations were recorded:
A total of 6 rats were assigned randomly to the Control group (n = 3) and
T2DM group (n = 3). The serum samples were immediately withdrawn just before the
animals were sacrificed, and kept in labeled Eppendorf tubes at room temperature for
30 minutes; to clot. Then, the tubes were centrifuged at 3,000 rpm for 10 minutes; to
separate the clot from the serum. The serum samples were kept in fresh labeled
Eppendorf tubes and stored at –80°C. From each serum sample, the total RNA was
extracted and reverse transcribed to cDNA. The expression of miR-20a, miR-21, miR29a, miR-31, and miR-155 in sera was determined by q-RT PCR.
There was a non-significant increase of miR-21 expression in the sera of 8
weeks of the onset of type 2 diabetes mellitus, as shown in Figure 12.
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Figure 12: The expression of miR-21 is upregulated in the sera of 8 weeks type 2
diabetic rat models.
Total RNA isolated from serum samples of control (n = 3) and type 2 diabetic (n = 3)
rats were analyzed by q-RT PCR to quantify miR-21 (p = 0.4140) and normalized
against U6 snoRNA to plot the relative expression of miR-21. Student’s t-test, error
bars indicate Standard Error of Mean (SEM).
3.5 Identification of MicroRNAs in Sera of 10 Weeks of the Onset of Type 2
Diabetes Mellitus
The expression of miR-20a, miR-21, miR-29a, miR-31, and miR-155 was
investigated in the sera of 10 weeks of the onset of type 2 diabetes mellitus.
Quantification Real-Time PCR was performed to analyze their expression using the
comparative delta-delta Ct method. U6 snRNA was used as an internal control for
normalization. Each experiment was performed in duplicates and repeated three times.
The following observations were recorded:
There was a significant reduction of miR-21 (p < 0.05) in the sera of 10 weeks
of the onset of type 2 diabetes mellitus (Figure 13).
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Figure 13: The expression of miR-21 is significantly downregulated in the sera of 10
weeks type 2 diabetic rat model.
Total RNA isolated from serum samples of control (n = 3) and type 2 diabetic (n = 3)
rats were analyzed by q-RT PCR to quantify miR-21 (p = 0.0513) and normalized
against U6 snoRNA to plot the relative expression of miR-21. (Student’s t-test, error
bars indicate Standard Error of Mean (SEM), * indicates significant differences at p
< 0.05).
3.6 Identification of MicroRNAs in Sera of 14 Weeks of the Onset of Type 2
Diabetes Mellitus
The expression of miR-20a, miR-21, miR-29a, miR-31, and miR-155 in the
sera of 14 weeks of the onset of type 2 diabetes mellitus were studied. Quantification
Real-Time PCR was performed to analyze their expression using the comparative
delta-delta Ct method. U6 snRNA was used as an internal control for normalization.
Each experiment was performed in duplicates and repeated three times. The following
observations were recorded:
There was a significant elevation of miR-155 (p < 0.01) expression in the sera
of 14 weeks of the onset of type 2 diabetes mellitus, as displayed in Figure 14.
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Figure 14: The expression of miR-155 is significantly upregulated in the sera of 14
weeks type 2 diabetic rat model.
Total RNA isolated from serum samples of control (n = 3) and type 2 diabetic (n = 3)
rats were analyzed by q-RT PCR to quantify miR-155 (p = 0.0102) and normalized
against U6 snoRNA to plot the relative expression of miR-155. (Student’s t-test,
error bars indicate Standard Error of Mean (SEM), ** indicates significant
differences at p < 0.01).
3.7 Identification of MicroRNA Target Genes in Bones of 8 Weeks of the Onset
of Type 2 Diabetes Mellitus
In the bones of 8 weeks of the onset of type 2 diabetes mellitus, 23 target genes
that are known by the literature review to be controlled by miR-20a, miR-21, miR29a, miR-31, and miR-155 were examined. The 23 target genes are as follows:
1. ATG16L1→ Autophagy Related 16 Like 1.
2. Bambi → Bone Morphogenetic Protein and Activin Membrane-Bound Inhibitor.
3. BMP2→ Bone Morphogenetic Protein 2.
4. BMP3 → Bone Morphogenetic Protein 3.
5. CALCA → Calcitonin Related Polypeptide Alpha.
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6. CRIM1→ Cysteine-rich transmembrane BMP regulator 1.
7. DKK1→ Dickkopf WNT Signaling Pathway Inhibitor 1.
8. KREMEN2 → Kringle Containing Transmembrane Protein 2.
9. MITF → Microphthalmia-associated transcription factor.
10. PDCD4 → Programmed cell death protein 4.
11. PPARG → Peroxisome proliferator-activated receptor gamma.
12. RhoA → Ras homolog family member A.
13. RUNX2 → Runt-related transcription factor 2 [CBFA1].
14. SATP2 → Special AT-Rich Sequence-Binding Protein 2.
15. SFRP2 → Secreted frizzled-related protein 2.
16. SMAD7 → Caenorhabditis elegans SMA ("small" worm phenotype) and
Drosophila MAD ("Mothers Against Decapentaplegic") [Smad family member
7].
17. SOCS1→ Suppressor of cytokine signaling 1 [STAT-induced STAT inhibitor 1
(SSI)].
18. SOST → Sclerostin.
19. SP7 → Sp7 Transcription Factor [Osterix].
20. SRF → Serum Response Factor.
21. TGFB1 → Transforming Growth Factor Beta 1.
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22. TNFRSF11P → Tumor necrosis factor receptor superfamily member 11b [OPG].
23. TNFSF11 → Tumor Necrosis Factor Ligand Superfamily Member 11 [RANKL].
Quantification Real-Time PCR was performed to analyze their expression
using the comparative delta-delta Ct method. Actin-Beta was used as an internal
control for normalization. Each experiment was performed in duplicates and repeated
three times. The following observations were recorded:
Among the 23 target genes, the expression of the RhoA gene and SOCS1 gene
were detected.
RhoA (p < 0.05) gene expression was significantly lowered in 8 weeks type 2
diabetic rat bone tissue (Figure 15).
SOCS1 (p < 0.05) gene expression was significantly decreased in the bones of
8 weeks of the onset of type 2 diabetes mellitus (Figure 16).

Figure 15: The expression of the RhoA gene is significantly downregulated in 8
weeks type 2 diabetic rat bone tissue.
Total RNA isolated from tibiae bone samples of control (n = 3) and T2DM (n = 3)
rats were analyzed by q-RT PCR and normalized against Actin-Beta to plot the
relative expression of RhoA (p = 0.0425) gene. (Student’s t-test, error bars indicate
Standard Error of Mean (SEM), * indicates significant differences at p < 0.05).
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Figure 16: The expression of the SOCS1 gene is significantly downregulated in 8
weeks type 2 diabetic rat bone tissue.
Total RNA isolated from tibiae bone samples of control (n = 3) and T2DM (n = 3)
rats were analyzed by q-RT PCR and normalized against Actin-Beta to plot the
relative expression of SOCS1 (p = 0.0260) gene. (Student’s t-test, error bars indicate
Standard Error of Mean (SEM), * indicates significant differences at p < 0.05).
3.8 Identification of MicroRNA Target Genes in Bones of 10 Weeks of the Onset
of Type 2 Diabetes Mellitus
The 23 target genes were studied in the bones of 10 weeks of the onset of type
2 diabetes mellitus. Quantification Real-Time PCR was performed to analyze their
expression using the comparative delta-delta Ct method. Actin-Beta was used as an
internal control for normalization. Each experiment was performed in duplicates and
repeated three times. The following observations were recorded:
From the 23 target genes, the expression of the RhoA gene, SOCS1 gene, and
PDCD4 gene was successfully detected.
There was a significant increase in the expression of the RhoA (p < 0.05) gene
in 10 weeks type 2 diabetic rat bone tissue, as shown in Figure 17.
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There was a non-significant increase in the expression of the SOCS1 gene in
the bones of 10 weeks of the onset of type 2 diabetes mellitus (Figure 18).
There was a non-significant elevation in the expression of PDCD4 gene in 10
weeks type 2 diabetic rat bone tissue (Figure 19).

Figure 17: The expression of the RhoA gene is significantly upregulated in 10 weeks
type 2 diabetic rat bone tissue.
Total RNA isolated from tibiae bone samples of control (n = 3) and T2DM (n = 3)
rats were analyzed by q-RT PCR and normalized against Actin-Beta to plot the
relative expression of RhoA (p = 0.047) gene. (Student’s t-test, error bars indicate
Standard Error of Mean (SEM), * indicates significant differences at p < 0.05).
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Figure 18: Upregulation of the SOCS1 gene expression in 10 weeks type 2 diabetic
rat bone tissue.
Total RNA isolated from tibiae bone samples of control (n = 3) and T2DM (n = 3)
rats were analyzed by q-RT PCR and normalized against Actin-Beta to plot the
relative expression of SOCS1 (p = 0.226) gene. Student’s t-test, error bars indicate
Standard Error of Mean (SEM).

Figure 19: Upregulation of the PDCD4 gene expression in 10 weeks type 2 diabetic
rat bone tissue.
Total RNA isolated from tibiae bone samples of control (n = 3) and T2DM (n = 3)
rats were analyzed by q-RT PCR and normalized against Actin-Beta to plot the
relative expression of the PDCD4 (p = 0.3483) gene. Student’s t-test, error bars
indicate Standard Error of Mean (SEM).
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3.9 Identification of MicroRNA Target Genes in Bones of 14 Weeks of the Onset
of Type 2 Diabetes Mellitus
The 23 target genes were studied in the bones of 14 weeks of the onset of type
2 diabetes mellitus. Quantification Real-Time PCR was performed to analyze their
expression using the comparative delta-delta Ct method. Actin-Beta was used as an
internal control for normalization. Each experiment was performed in duplicates and
repeated three times. The following observations were recorded:
Among the 23 target genes, the expression of the RhoA gene and the SOCS1
gene were detected.
The expression of the RhoA gene was non-significantly decreased in 14 weeks
type 2 diabetic rat bone tissue, as displayed in Figure 20.
The expression of the SOCS1 (p < 0.05) gene was significantly lowered in the
bones of 14 weeks of the onset of type 2 diabetes mellitus (Figure 21).

Figure 20: Downregulation of the RhoA gene expression in 14 weeks type 2 diabetic
rat bone tissue.
Total RNA isolated from tibiae bone samples of control (n = 3) and T2DM (n = 3)
rats were analyzed by q-RT PCR and normalized against Actin-Beta to plot the
relative expression of the RhoA (p = 0.3609) gene. Student’s t-test, error bars
indicate Standard Error of Mean (SEM).
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Figure 21: The expression of the SOCS1 gene is significantly downregulated in 14
weeks type 2 diabetic rat bone tissue.
Total RNA isolated from tibiae bone samples of control (n = 3) and T2DM (n = 3)
rats were analyzed by q-RT PCR and normalized against Actin-Beta to plot the
relative expression of SOCS1 (p = 0.0442) gene. (Student’s t-test, error bars indicate
Standard Error of Mean (SEM), * indicates significant differences at p < 0.05).
3.10 Measurement of Osteocalcin Level in Sera and Bones of 8, 10, and 14 Weeks
of the Onset of Type 2 Diabetes Mellitus
The bone turnover rate of the 8, 10, and 14 weeks of the duration of type 2
diabetes mellitus was studied by checking their serum and bone osteocalcin level,
which is a biomarker for the process of bone formation. The serum osteocalcin level
was performed using an ELISA kit for osteocalcin (Cloud-Clone Corp. / SEA471Ra),
and the bone osteocalcin level was performed using Rat Osteocalcin ELISA kit
(Abbkine / KTE101053). The following observations were recorded:
The serum osteocalcin level in the sera of 8 weeks of the duration of type 2
diabetes mellitus was dropped significantly (p < 0.05) (Figure 22).
There was a non-significant increase in the serum osteocalcin level in the sera
of 10 weeks of the duration of type 2 diabetes mellitus (Figure 22).
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In the sera of 14 weeks of the duration of type 2 diabetes mellitus, the
difference in the osteocalcin levels was non-significant and not much difference
(Figure 22).
The bone osteocalcin levels in 8 weeks of the duration of T2DM were
decreased, and in 10 and 14 weeks were increased. However, the results obtained were
not significant (Figure 23).

Figure 22: Osteocalcin level is significantly decreased in the sera of 8 weeks,
increased in the sera of 10 weeks, and no change in the sera of 14 weeks.
Serum samples of control (n = 3) and T2DM (n = 3) rats in the duration of 8, 10, and
14 weeks were analyzed by Enzyme-linked Immunosorbent Assay [ELISA] Kit For
Osteocalcin [OC] (Cloud-Clone Corp. / SEA471Ra) to plot the level of serum
osteocalcin (ng/ml). (Student’s t-test, error bars indicate Standard Error of Mean
(SEM), * indicates significant differences at p < 0.05).
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Figure 23: Osteocalcin level is decreased in the bones of 8 weeks, increased in the
bones of 10 weeks, and increased in the bones of 14 weeks.
Bone samples of control (n = 3) and T2DM (n = 3) rats in the duration of 8 (p =
0.5201), 10 (p = 0.3276), and 14 (p = 0.0661) weeks were analyzed by Rat
Osteocalcin ELISA Kit (Abbkine / KTE101053) to plot the level of bone osteocalcin
(pg/mg). Student’s t-test, error bars indicate Standard Error of Mean (SEM).
3.11 Summary of the Results
All the results that were achieved in this study from Sections 3.1 – 3.10 were
summarized in Figure 24 and Tables 2, 3 and 4. In this study, the bones of type two
diabetic rats were observed at week 8, 10 and 14, the expression of miR-20a, miR-21,
miR-29a, miR-31, and miR-155 were altered. The log2 fold changed expression of
miR-20a, miR-21, miR-29a, miR-31, and miR-155 in the bones of type 2 diabetic rats
at 8 weeks, 10 weeks, and 14 weeks duration is displayed in Figure 24. The expression
of miR-20a, miR-21, miR-29a, miR-31, and miR-155 in the bones and sera of 8 weeks
of the duration of T2DM, as well as, the expression of the detected target genes and
the serum and bone osteocalcin level is shown in Table 2. The expression of the five
selected microRNAs in the bones and sera of 10 weeks of the duration of T2DM and
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the expression of the detected target genes and the serum and bone osteocalcin level is
shown in Table 3. The expression of the five selected microRNAs in the bones and
sera of 14 weeks of the duration of T2DM and the expression of the detected target
genes and the serum and bone osteocalcin level are presented in Table 4.

Figure 24: Schematic overview of the expression of miR-20a, miR-21, miR-29a, miR-31, and miR-155 in bones of type 2 diabetic rats at 8
weeks, 10 weeks, and 14 weeks duration.
The bars represent the log2 fold change of each microRNA at each of the three time points. The log2 fold change was calculated by using this
formula: [Log ((T2DM/Control), 2)]. (Student’s t-test, * indicates significant differences at p < 0.05).
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Table 2: The expression of miR-20a, miR-21, miR-29a, miR-31, and miR-155 in bones and sera of 8 weeks of the onset of T2DM, the expression
of the detected target genes and the serum and bone osteocalcin level.

microRNA

miR-20a

miR-21

miR-29a

miR-31

miR-155

T2DM
(8 weeks duration)
Bone samples

T2DM
(8 weeks duration)
Serum samples

Target Genes

 ATG16L1 (N/D)
 BAMBI (N/D)
Decreased
(N/D)
 BMP2 (N/D)
 BMP3 (N/D)
 CALCA (N/D)
 CRIM1 (N/D)
Increased
Increased
 DKK1 (N/D)
 KREMAN2 (N/D)
 MITF (N/D)
 PDCD4 (N/D)
 PPARG (N/D)
Increased
(N/D)
 RhoA [Decreased]*
 RUNX2 (N/D)
 SATB2 (N/D)
 SFRP2 (N/D)
 SMAD7 (N/D)
Increased
(N/D)
 SOCS1 [Decreased]*
 SOST (N/D)
 SP7 (N/D)
 SRF (N/D)
 TGFB1(N/D)
Decreased
(N/D)
 TNFRSF11B [OPG] (N/D)
 TNFSF11 [RANKL] (N/D)
* = indicates significant differences at p < 0.05 (Student’s t-test)

Serum OC

Bone OC

Decreased*

Decreased

(N/D) = Not Detected
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Table 3: The expression of miR-20a, miR-21, miR-29a, miR-31, and miR-155 in bones and sera of 10 weeks of the onset of T2DM, the
expression of the detected target genes and the serum and bone osteocalcin level.

microRNA

miR-20a

miR-21

miR-29a

miR-31

miR-155

T2DM
(10 weeks duration)
Bone samples

T2DM
(10 weeks duration)
Serum samples

Target Genes

 ATG16L1 (N/D)
 BAMBI (N/D)
Decreased*
(N/D)
 BMP2 (N/D)
 BMP3 (N/D)
 CALCA (N/D)
 CRIM1 (N/D)
 DKK1 (N/D)
Decreased*
Decreased*
 KREMAN2 (N/D)
 MITF (N/D)
 PDCD4 [Increased]
 PPARG (N/D)
 RhoA [Increased]*
Decreased
(N/D)
 RUNX2 (N/D)
 SATB2 (N/D)
 SFRP2 (N/D)
 SMAD7 (N/D)
Decreased
(N/D)
 SOCS1 [Increased]
 SOST (N/D)
 SP7 (N/D)
 SRF (N/D)
 TGFB1 (N/D)
Decreased*
(N/D)
 TNFRSF11B [OPG] (N/D)
 TNFSF11 [RANKL] (N/D)
* = indicates significant differences at p < 0.05 (Student’s t-test)

Serum OC

Bone OC

Increased

Increased

(N/D) = Not Detected
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Table 4: The expression of miR-20a, miR-21, miR-29a, miR-31, and miR-155 in bones and sera of 14 weeks of the onset of T2DM, the
expression of the detected target genes and the serum and bone osteocalcin level.

microRNA

miR-20a

miR-21

miR-29a

miR-31

miR-155

T2DM
(14 weeks duration)
Bone samples

T2DM
(14 weeks duration)
Serum samples

Target Genes

 ATG16L1(N/D)
 BAMBI (N/D)
Increased
(N/D)
 BMP2 (N/D)
 BMP3 (N/D)
 CALCA (N/D)
 CRIM1 (N/D)
 DKK1 (N/D)
Decreased
(N/D)
 KREMAN2 (N/D)
 MITF (N/D)
 PDCD4 (N/D)
 PPARG (N/D)
Decreased
(N/D)
 RhoA [Decreased]
 RUNX2 (N/D)
 SATB2 (N/D)
 SFRP2 (N/D)
 SMAD7 (N/D)
Decreased
(N/D)
 SOCS1 [Decreased]*
 SOST (N/D)
 SP7 (N/D)
 SRF (N/D)
 TGFB1 (N/D)
Increased
Increased**
 TNFRSF11B [OPG] (N/D)
 TNFSF11 [RANKL] (N/D)
** = indicates significant differences at p < 0.01 (Student’s t-test)

Serum OC

Bone OC

No change

Increased

* = indicates significant differences at p < 0.05 (Student’s t-test)
(N/D) = Not Detected
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3.12 Analysis of Histological Changes in Bones of 8, 10, and 14 Weeks of the Onset
of Type 2 Diabetes Mellitus
The proximal head of the femur is used for histologic analysis. In Figure 25, it
illustrates an example of the proximal head of a femur and the region of interest [ROI]
that is used for histologic examination in this study.
In subsection 3.12.1, the results of the trabecular measurements are explained.
In Figure 26, it identifies the main features of a bone section (proximal head of the
femur).
In subsection 3.12.2, the results of the quantitative analysis of apoptotic and
live cells are explained. In Figure 27, it’s pointing the live and apoptotic cells.

(a)

(b)

Figure 25: Histologic examination of the proximal head of a control femur.
Hematoxylin & Eosin staining, (a) Proximal head of a femur (Scale bar = 1000 μm), showing the region of interest (ROI) [the selected area]
that is used for histologic analysis, (b) Example of a histologic section (Scale bar = 200 μm).
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Figure 26: Masson's Trichrome staining of a control bone (proximal head of the femur).
Masson’s Trichrome staining identifies collagen (blue), osteoid (red), osteocytes (dark blue dots). Scale bar = 200 μm.
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(a)

(b)

Figure 27: TUNEL staining of a bone section (proximal head of the femur).
TUNEL staining, (a) Control, showing live cells (blue dots), (b) T2DM, showing apoptotic cells (brown dots). Scale bar = 200 μm.

89

90
3.12.1 Trabecular Measurements
The trabecular measurements consist of trabecular bone volume (BV/TV),
trabecular separation (Tb. Sp), trabecular thickness (Tb. Th), and trabecular number
(Tb. N). Trabecular bone volume is expressed as a %, it is defined as the relative
volume of the total trabecular bone. Trabecular separation is the mean distance
between the trabecular plates (Figure 28). Trabecular thickness is the mean distance of
the trabecular structure, and it is calculated as (1/Tb.Sp) (Figure 28). The trabecular
number is the number of trabeculae per lineal mm, it is calculated as ([BV/TV]/Tb.Th).

Figure 28: Definition of the two of the trabecular measurements (trabecular thickness
and separation).
Trabecular thickness (Tb. Th), shown in the yellow arrow, is the distance
measurement of the trabecula, and trabecular separation (Tb. Sp), shown in the green
arrow, is the distance measurement between trabecular plates.
The bone sections of the control rats at 8, 10, 14 weeks duration, and as well
as the bone sections of the T2DM rats at 8, 10, and 14 weeks duration, which was used
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to perform the trabecular measurements are presented in Figure 29.
The BV/TV was significantly reduced in 8 (p < 0.05), 10 (< 0.0001), and 14 (p
< 0.05) of the duration of T2DM (Figure 30).
The Tb. Sp of 14 (p < 0.001) weeks of the duration of T2DM were significantly
raised, the Tb. Sp was non-significantly increased in 10 weeks of the duration of
T2DM, and there was no notable change of Tb.Sp in 8 weeks of the duration of T2DM
from the 8 weeks control (Figure 31).
The Tb. Th of 14 (p < 0.01) weeks of the duration of T2DM was significantly
dropped, the Tb. Th was non-significantly reduced in 10 weeks of the duration of
T2DM, and there was no notable change of Tb. Th in the 8 weeks of the duration of
T2DM from the 8 weeks control (Figure 32).
The Tb. N of 10 (p < 0.05) weeks of the duration of T2DM was significantly
decreased, and there was a non-significant decrease in the Tb. N of 8 and 14 weeks of
the duration of T2DM (Figure 33).

(a)

(b)

(c)

(d)

(e)

(g)

Figure 29: Masson’s Trichrome staining of the bone sections (proximal head of the femur).
Masson’s Trichrome staining, (a) Control [8 weeks duration], (b) Control [10 weeks duration], (c) Control [14 weeks duration], (d) T2DM [8
weeks duration], (e) T2DM [10 weeks duration], and (g) T2DM [14 weeks duration]. Scale bar = 200 μm.
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Figure 30: Significant decrease in BV/TV of T2DM rats at 8, 10, and 14 weeks
duration.
Masson’s Trichrome stained bone sections (proximal head of the femur) of
control (n = 3) and T2DM (n = 3) rats in the duration of 8 (p = 0.0286), 10 (p =
0.000015), and 14 (p = 0.0423)weeks were analyzed by using the application
Image J to plot the trabecular bone volume [BV/TV] (%). (Student’s t-test, Error
bars indicate Standard Error of Mean (SEM), * indicates significant differences at
p < 0.05, **** indicates significant differences at p < 0.0001).

Figure 31: Tb.Sp in 14 weeks is significantly increased, increased in 10 weeks,
and no change in 8 weeks.
Masson’s Trichrome stained bone sections (proximal head of the femur) of
control (n = 3) and T2DM (n = 3) rats in the duration of 8 (p = 0.4957), 10 (p =
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0.140), and 14 (p = 0.0011) weeks were analyzed by using the application ImageJ
to plot the trabecular separation [Tb.Sp] (mm). (Student’s t-test, Error bars
indicate Standard Error of Mean (SEM), *** indicates significant differences at p
< 0.001).

Figure 32: Tb.Th in 14 weeks is significantly decreased, decreased in 10 weeks, and
no change in 8 weeks.
Masson’s Trichrome stained bone sections (proximal head of the femur) of control (n
= 3) and T2DM (n = 3) rats in the duration of 8 (p = 0.4589), 10 (p = 0.1544), and 14
(p = 0.0029) weeks were analyzed by calculating 1/Tb.Sp to plot the trabecular
thickness [Tb. Th] (mm). (Student’s t-test, Error bars indicate Standard Error of
Mean (SEM), ** indicates significant differences at p < 0.01).

Figure 33: Significant decrease in Tb. N of 10 weeks of the onset of T2DM, and
decrease in Tb. N of 8 and 14 weeks of the onset of T2DM.
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Masson’s Trichrome stained bone sections (proximal head of the femur) of control (n
= 3) and T2DM (n = 3) rats in the duration of 8 (p = 0.1796), 10 (p = 0.0398) and 14
(p = 0.2964) weeks were analyzed by calculating [BV/TV]/Tb.Th to plot the
trabecular number [Tb. N] (1/mm). (Student’s t-test, Error bars indicate Standard
Error of Mean (SEM), * indicates significant differences at p < 0.05).
3.12.2 Quantitative Analysis of Apoptotic and Live Cells
The bone sections were taken from the proximal femur of the control rats at
8, 10, 14 weeks duration, and as well as the bone sections were taken from the
proximal femur of the T2DM rats at 8, 10, and 14 weeks duration, which was used to
count the apoptotic and live cells, as shown in Figure 34.
The number of apoptotic cells (p < 0.05) was significantly elevated in 8
weeks of the duration of T2DM, while the number of live cells was non-significantly
reduced (Figure 35).
There was a significant increase in the number of apoptotic cells (p < 0.05) in
10 weeks of the duration of T2DM, whereas there was a significant drop in the
number of live cells (p < 0.001) in 10 weeks of T2DM (Figure 36).
The number of apoptotic cells (p < 0.05) was significantly raised in 14 weeks
of the duration of T2DM, while the number of live cells (p < 0.05) was significantly
decreased (Figure 37).

(a)

(b)

(c)

(d)

(e)

(g)

Figure 34: TUNEL staining of the bone sections (proximal head of the femur).
TUNEL staining, (a) Control [8 weeks duration], (b) Control [10 weeks duration], (c) Control [14 weeks duration], (d) T2DM [8 weeks
duration], (e) T2DM [10 weeks duration], and (g) T2DM [14 weeks duration]. Scale bar = 200 μm.
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Figure 35: Significant increase of apoptotic cells in 8 weeks of the onset of T2DM,
and a decrease of live cells in 8 weeks of the onset of T2DM.
TUNEL stained bone sections (proximal head of the femur) of control (n = 3) and
T2DM (n = 3) rats in the duration of 8, 10, and 14 weeks were analyzed by counting
the apoptotic cells and the live cells per section to plot the mean counts
(count/section). (Student’s t-test, Error bars indicate Standard Error of Mean (SEM),
* indicates significant differences at p < 0.05, ** indicates significant differences at p
< 0.01). (Apoptotic cells-Control vs Apoptotic cells-T2DM, p = 0.0139), (Live cellsControl vs Live cells, p = 0.1702), (Control-Apoptotic vs Live cells, p = 0.0096),
(T2DM-Apoptotic vs Live cells, p = 0.0463).

Figure 36: Significant increase of apoptotic cells in 10 weeks of the onset of T2DM,
and a significant decrease in live cells in 10 weeks of the onset of T2DM.
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TUNEL stained bone sections (proximal head of the femur) of control (n = 3) and
T2DM (n = 3) rats in the duration of 8, 10, and 14 weeks were analyzed by counting
the apoptotic cells and the live cells per section to plot the mean counts
(count/section). (Student’s t-test, Error bars indicate Standard Error of Mean (SEM),
* indicates significant differences at p < 0.05, ** indicates significant differences at p
< 0.01, *** indicates significant differences at p < 0.001). (Apoptotic cells-Control
vs Apoptotic cells-T2DM, p = 0.0330), (Live cells-Control vs Live cells, p =
0.00095), (Control-Apoptotic vs Live cells, p = 0.0018), (T2DM-Apoptotic vs Live
cells, p = 0.1104).

Figure 37: Significant increase of apoptotic cells in 14 weeks of the onset of T2DM,
and a significant decrease in live cells in 14 weeks of the onset of T2DM.
TUNEL stained bone sections (proximal head of the femur) of control (n = 3) and
T2DM (n = 3) rats in the duration of 8, 10, and 14 weeks were analyzed by counting
the apoptotic cells and the live cells per section to plot the mean counts
(count/section). (Student’s t-test, Error bars indicate Standard Error of Mean (SEM),
* indicates significant differences at p < 0.05). (Apoptotic cells-Control vs Apoptotic
cells-T2DM, p = 0.0213), (Live cells-Control vs Live cells, p = 0.0418), (ControlApoptotic vs Live cells, p = 0.0157), (T2DM-Apoptotic vs Live cells, p = 0.0796).
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3.13 Significant Results
The significant results were gathered in Table 5.
Table 5: The significant results.
T2DM
1. Decreased expression of RhoA gene.
(8 weeks duration)
2. Decreased expression of SOCS1 gene.
Bone samples
T2DM
(10 weeks
duration)
Bone samples

1. Decreased expression of miR-20a.
2. Decreased expression of miR-21.
3. Decreased expression of miR-155.
4. Increaed expression of RhoA gene.

T2DM
(14 weeks
duration)
Bone samples

1. Decreased expression of SOCS1 gene.

T2DM
(8 weeks duration) 1. Decreased osteocalcin level.
Serum samples
T2DM
(10 weeks
duration)
Serum samples

1. Decreased expression of miR-21.

T2DM
(14 weeks
duration)
Serum samples

1. Increased expression of miR-155.
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Chapter 4: Discussion
The constant status of elevated blood glucose level is one of the characteristics
of non-insulin-dependent [type 2] diabetes mellitus (Hurtado & Vella, 2018). Insulin
resistance and impaired secretion of insulin are the mechanisms by which this
metabolic disorder is posing (Hurtado & Vella, 2018). One of the complications of
having the onset of type 2 diabetes mellitus is encountering osteoporosis (Zhao et al.,
2019). The most recognized definition of osteoporosis is a disorder that leads to
fracture susceptibility and accelerated levels of bone fragility observed by the
decreased levels of bone mass and the deterioration of the microarchitecture of the
bone tissue (Compston et al., 2019). Normally, gene expression is controlled through
a process called RNA interference by a small endogenous non-coding RNA molecule
called microRNAs (Bellavia et al., 2019). MicroRNA works by targeting the mRNA
of a gene and results in gene silencing (Bellavia et al., 2019). Therefore, an increased
level of microRNAs inhibits gene expression and decreased levels of microRNAs
promote gene expression (Bellavia et al., 2019). Current studies have revealed that the
levels of microRNAs are varied between diseases, as a consequence, those microRNAs
could be used as diagnostic biomarkers for certain diseases like osteoporosis (Bellavia
et al., 2019). Based on that the study aimed to investigate the bone remodeling cycle
modulators in type 2 diabetes mellitus through microRNAs.
In this study, the mode of modulation in the bone remodeling cycle was
investigated by testing the expression of miR-20a, miR-21, miR-29a, miR-31, and
miR-155 in the bones and sera of 8, 10, and 14 weeks of the onset of T2DM.
Furthermore, some of their possible target genes were tested as well in the bones of 8,
10, and 14 weeks of the onset T2DM. The serum osteocalcin level was tested in the
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sera of 8, 10, and 14 weeks of the onset of T2DM. In addition to that, the bone
osteocalcin level was tested in the bones of 8, 10, and 14 weeks of the onset of T2DM.
The bone microstructure was analyzed using histological techniques for the bones of
8, 10, and 14 weeks of the onset of T2DM.
According to the literature review, downregulation of miR-20a increases the
expression of a gene essentially involved in autophagy, ATG16L1 (Autophagy related
16 like 1), which, promotes osteoclast differentiation (Sun et al., 2015). The
maintenance of osteocyte homeostasis is regulated by autophagy (Yin et al., 2019).
High reactive oxygen species (ROS) and hypoxia are the adverse factors that threats
osteocytes survival (Yin et al., 2019). Osteocytes depend on autophagy to sustain their
survival (Yin et al., 2019). Under high oxidative stress, the elevated autophagic activity
led to reduced osteocyte apoptosis (Yin et al., 2019). Osteocyte apoptosis is linked
with local bone resorption (Plotkin, 2014). The apoptotic osteocytes are devoured by
osteoclasts (Plotkin, 2014). Using caspase inhibitors, the osteocyte apoptosis was
stopped, which results in a decrease in bone resorption (Plotkin, 2014). In this study,
it’s have been observed that in the bones of 8 weeks of the onset of type 2 diabetes
mellitus, the expression of miR-20a was non-significantly decreased, the expression
of its target gene ATG16L1 was not detected, and the apoptotic cells were significantly
(p < 0.05) increased. This suggests that the increased apoptosis at 8 weeks of the onset
of T2DM could be the reason for enhanced bone resorption and osteoclastogenesis.
Previous studies have shown that the overexpression of miR-21 promotes
osteoblast differentiation by downregulating the SMAD7 gene, and promotes bone
resorption by downregulating PDCD4 (Bellavia et al., 2019; Hu et al., 2017). In this
study, the bones of 8 weeks of the onset of type 2 diabetes mellitus were analyzed, it
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revealed that the expression of miR-21 was non-significantly increased, the expression
of SMAD7 and PDCD4 however were not detected. The osteocalcin levels measured
in samples obtained from bone and serum showed decreased osteocalcin levels. The
data obtained from the serum osteocalcin was significant (p < 0.05). These results
speculate that miR-21 functions in suppressing osteoblast differentiation maybe acting
on other target genes; since the serum osteocalcin levels were significantly decreased,
which might suggest a reduced bone formation. Moreover, these results also suggest
that miR-21 functions in promoting bone resorption; since the samples showing a trend
towards increased miR-21, which most likely increasing bone resorption. But, in the
future, the need to investigate the biomarkers for bone resorption is necessary to back
up this suggestion.
The expression of miR-29a, miR-29b and miR-29c induces apoptosis by
upregulating p53 [tumor suppressor gene] (Park et al., 2009). Earlier researches
investigated that upregulation of miR-29a expression promotes osteoblast
differentiation (Bellavia et al., 2019; Ko et al., 2015). Moreover, the upregulation of
miR-29a expression also decreases non-collagenous matrix proteins such as
osteocalcin and osteonectin [ON], which leads to speeding up the extracellular
mineralization (Bellavia et al., 2019; Kapinas et al., 2009). A previous study has shown
that reduced non-collagenous matrix proteins indicate reduced osteoblast numbers
(Delany et al., 2003). Furthermore, many studies support the idea that the rate of
extracellular mineralization is controlled by apoptosis (An et al., 2015; Roy et al.,
2010). For example, if apoptosis is high, the rate of extracellular mineralization is
accelerated (Roy et al., 2010). In this study, it’s have been noticed that in the bones of
8 weeks of the onset of type 2 diabetes mellitus, the expression of miR-29a was
increased (non-significantly), suggesting that it might be affecting the bone
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remodeling cycle by accelerating extracellular mineralization; since the apoptosis cells
were significantly (p < 0.05) elevated. However, osteocalcin levels measures in bone
and serum showed decreased osteocalcin levels. The data obtained from the serum
osteocalcin was significant (p < 0.05). Reduced bone formation is indicated by the
reduced osteocalcin, which declares that the increased expression of miR-29a in the
bones of 8 weeks of the onset of T2DM could be through decreasing non-collagenous
matrix protein. In addition, reduced non-collagenous matrix protein means that there
are decreased number of osteoblasts, and that triggers the rate of extracellular
mineralization to be fast by differentiating those osteoblasts to osteocytes, and that's
approved by the significant increase of apoptotic cells in 8 weeks of the onset of
T2DM.
A previous study has shown that in osteoclast cells, the miR-31 target gene is
RhoA (Mizoguchi et al., 2013). The same previous study examined the
underexpression of RhoA by the overexpression of miR-31 induces osteoclastogenesis
(Mizoguchi et al., 2013). Equivalently, in this study, it’s have been observed that in
the bones of 8 weeks type 2 diabetic rats, the expression of miR-31 was nonsignificantly increased, and the expression of RhoA was significantly (p < 0.05)
decreased, indicating a possibility of induction in osteoclastogenesis. Bone resorption
markers will be measured to confirm osteoclast activity.
As shown in an earlier study, in osteoblast cells, the miR-155 target gene is
SOCS1 (Wua et al., 2012). An earlier study investigated that the underexpression of
SOCS1 by the overexpression of miR-155 suppresses osteoblast differentiation,
whereas the overexpression of SOCS1 by the underexpression of miR-155 partially
reduces the suppression of osteoblast differentiation (Wua et al., 2012). In this study,
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it’s have been noticed that in the bones of 8 weeks of the onset of type 2 diabetes
mellitus, the change in the expression of miR-155 was non-significant, but the
expression of SOCS1 was significantly (p < 0.05) decreased. The mode of modulation
in the bone remodeling cycle is more probably toward suppressing osteoblast
differentiation; because of the significant reduction in SOCS1 expression. This
suggestion was backed up by looking at the serum and bone osteocalcin level in 8
weeks of the onset of T2DM, which implies a reduced bone formation; since they were
decreased, the mode of modulation is probably going toward suppressing osteoblast
differentiation.
It's been examined in a past study that the downregulation of miR-20a causes
suppression of osteoblast differentiation (Jin-fang Zhang et al., 2011). In line with this,
it’s been found in this study that in the bones of 10 weeks of the duration of type 2
diabetes mellitus, the expression of miR-20a was significantly (p < 0.05) decreased.
These findings directs that the modulation of the bone remodeling cycle by the
decreased miR-20a is probably on the osteoblast, not the osteoclast.
A study has suggested that the PDCD4 gene is one of the miR-21 target genes
(Hu et al., 2017). It's been reported that the overexpression of the PDCD4 gene by the
underexpression of miR-21 causes suppression of osteoclastogenesis (Sugatani et al.,
2011). In this study, similarly it’s been observed that in the bones of 10 weeks of the
onset of type 2 diabetes mellitus, the expression of miR-21 was significantly (p < 0.05)
decreased, and the expression of PDCD4 was non-significantly increased, suggesting
a possibility of suppressing osteoclastogenesis.
The increased expression of miR-29a downregulates the negative regulators of
Wnt signaling [DKK1, KREMEN2, and SFRP2], which results in promoting
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osteoblast differentiation (Kapinas et al., 2010). Furthermore, the expression of miR29a reduces non-collagenous matrix proteins, which leads to acceleration in
extracellular mineralization (Kapinas et al., 2009). It’s been investigated that apoptosis
controls the rate of extracellular mineralization, the higher the apoptosis, the higher
the rate of extracellular mineralization (Roy et al., 2010). In this study, it’s has been
seen that in the bones of 10 and 14 weeks of the duration of type 2 diabetes mellitus,
the expression of miR-29a was non-significantly decreased, the expression of the
target genes, DKK1, KREMEN2, and SFRP2 were not detected in the samples.
Previous studies have shown miR-29a is necessary for human osteoblast
differentiation and

decreased miR-29a

levels increases in DKK1 levels and

suppresses the bone formation (Kapinas et al., 2010).
The apoptotic cells were significantly (p < 0.05) increased at the 10th and 14th
week of onset of T2DM. Although there was a significant increase of apoptotic cells
in 10th and 14th week of the onset of T2DM when compared with controls, there was
no significant difference between the apoptotic cells and the live cells within the group
of 10th and 14th week of the onset of T2DM. This means that the rate of extracellular
mineralization is not high, instead, it triggers the start of extracellular mineralization.
This study found that in the bones of 10 weeks of the onset of type 2 diabetes
mellitus, the expression of miR-31 was non-significantly decreased and the expression
of RhoA was significantly (p < 0.05) increased. The RhoA gene is one of the miR-31
target genes (Mizoguchi et al., 2013). The literature review suggested that the
inhibition of miR-31 leads to raised expression of the RhoA gene, which affects the
bone remodeling cycle by suppressing osteoclastogenesis and bone resorption
(Mizoguchi et al., 2013). Correspondingly in this study, indicating a possibility of
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suppression in osteoclastogenesis and bone resorption at 10 weeks of the onset of type
2 diabetes mellitus.
Osteoblast differentiation is inhibited by the expression of miR-155 through
downregulating SMAD proteins (Gu et al., 2017). SMAD7 is one the proteins involved
in Smad signaling (Xu et al., 2016). In this study, it’s been observed that in the bones
of 10 weeks of the onset of type 2 diabetes mellitus, the expression of miR-155 was
significantly (p < 0.05) decreased, and the expression of SMAD7 was not detected.
Decreased expression of miR-155 causes hyperglycemia, impaired glucose tolerance,
and insulin resistance (Lin et al., 2016).
As previous studies mentioned that the upregulation of miR-20a could affect
the osteoblasts by promoting their differentiation by downregulating the expression of
the PPARG gene, BAMBI gene, and CRIM1gene, which involved in differentiation
and developmental processes (Bellavia et al., 2019; Jin-fang Zhang et al., 2011). In
this study, a significant difference was not found in the expression of miR-20a levels
between control and diabetic bone samples with 14 weeks of the onset of type 2
diabetes mellitus, and the target gene PPARG, BAMBI, and CRIM1 were not detected.
PPARγ2 gene is linked to a genetic risk factor for type 2 diabetes mellitus and its effect
becomes more manifest when diabetes is accompanied by obesity (Pattanayak et al.,
2014).
It’s been investigated in the literature review that the silencing of miR-21
affects the bone remodeling cycle by impairing osteoclastogenesis through
overexpression of PDCD4 (Sugatani et al., 2011). Equivalently, in this study, it’s been
noticed that in the bones of 14 weeks of the onset of type 2 diabetes mellitus, the
expression of miR-21 was non-significantly decreased, and the expression of the target
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gene PDCD4 was not detected. These results suggest a possible impairment of
osteoclastogenesis.
The overexpression of the RhoA gene by the inhibition of miR-31 leads to the
suppression of osteoclastogenesis and bone resorption, whereas the overexpression of
miR-31 downregulates the RhoA gene, which leads to the promotion of
osteoclastogenesis (Mizoguchi et al., 2013). In this study, it’s been noticed that in the
bones of 14 weeks of the onset of type 2 diabetes mellitus, the expression of miR-31
was non-significantly decreased, and the expression of RhoA was non-significantly
decreased as well; could be due to less number of samples. It is hard to claim which
mode of modulation in the bone remodeling cycle is miR-31 posing in 14 weeks of the
onset of T2DM. MiR-31 is a positive regulator of osteoclast formation and bone
resorption.
The overexpression of miR-155 downregulates the SOCS1 gene, which results
in suppressing osteoblast differentiation (Wua et al., 2012). Thus in this study, it’s
been found out that in the bones of 14 weeks of the onset of type 2 diabetes mellitus,
the expression of miR-155 was non-significantly increased, and the expression of miR155 was significantly (p < 0.01) increased in the sera of 14 weeks of the onset of
T2DM. Moreover, the expression of SOCS1 was significantly (p < 0.05) decreased,
indicating a possible suppression of osteoblast differentiation.
Clinically, microRNA drugs can be used to treat certain diseases through
suppressing or promoting the levels of mRNA based on recent in-vivo studies (Roser
et al., 2018). Based on that idea, it might be possible to detect the expression of the
microRNAs in serum samples; to use them clinically for diagnosis. In this study, the
expression of miR-21 in the sera of 8 weeks of the duration of T2DM was increased
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non-significantly (p = 0.4140), which is matching with the result of the bones of 8
weeks of the duration of T2DM. In addition, the expression of miR-21 in the sera of
10 weeks of the duration of T2DM was significantly (p = 0.0513) decreased, and this
result goes in line with the result of the bones of 10 weeks of the duration of T2DM.
The expression of miR-155 in the sera of 14 weeks of the duration of T2DM was
significantly (p = 0.0102) increased, and that's equivalent to the result of the bones of
14 weeks of the duration of T2DM. These findings suggest that those microRNAs
could be highly expressed in sera compared to the other microRNAs and can be used
as potential biomarkers.
By the use of a micro-CT, the previous study characterized the trabecular
microarchitecture of the T2DM femoral head, the study stated a significant elevation
in trabecular separation and a decrease in bone volume, trabecular number, and
thickness (Mohsin et al., 2019). In addition to that, the study suggested that the
trabecular structure was affected negatively by the onset of T2DM, and that increases
the risk of hip fractures (Mohsin et al., 2019). The data obtained in this study using the
histological techniques is consistent with an earlier study (Mohsin et al., 2019). It was
found that there was a significant decrease (p <0.05) in trabecular bone volume in 10
and 14 weeks of the onset of T2DM. For the trabecular separation, there was a
significant (p < 0.001) increase in 14 weeks of the onset of T2DM, an non-significant
increase in 10 weeks of the onset of T2DM and no change in 8 weeks of the onset of
T2DM. For the trabecular thickness, there was a significant (p < 0.01) decrease in 14
weeks of the onset of T2DM, a non-significant decrease in 10 weeks of the onset of
T2DM, and no change in 8 weeks of the onset of T2DM. For the trabecular number,
there was a significant (p < 0.05) decrease in 10 weeks of the onset of T2DM, and a
non-significant decrease in 8 and 14 weeks of the onset of T2DM. These trabecular
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measurements indicate that type 2 diabetes mellitus have an adverse effect on the
trabecular structure, suggesting increased susceptibility to hip fractures.
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Chapter 5: Conclusion
To sum up, miR-20a, miR-21, miR-29a, miR-31, and miR-155 are known to
be responsible to regulate the bone remodeling cycle, and their dysregulation has been
described in bone disorders like osteoporosis.
The study 1) identified the changes in some miRNAs levels related to bone
remodeling cycle in bones of type 2 diabetic rats, 2) measured the miRNAs in the sera
to use them as a potential biomarker, and 3) investigated the target genes for those
miRNAs to understand the mechanisms involved in skeletal fragility related to T2DM
and their potential use in therapeutics.
This current study revealed that in 8 weeks of the duration of T2DM, the
dysregulation of miR-20a, miR-21, miR-29a, miR-31, and miR-155 affects the bone
remodeling cycle by promoting osteoclastogenesis, and suppressing osteoblast
differentiation. In 10 weeks of the duration of T2DM, the dysregulation of miR-20a,
miR-21, miR-29a, miR-31, and miR-155 affects the bone remodeling cycle by
suppressing osteoclastogenesis, and suppressing bone formation. In 14 weeks of the
duration of T2DM, the dysregulation of miR-20a, miR-21, miR-29a, miR-31, and
miR-155 affects the bone remodeling cycle by suppressing osteoclastogenesis and
suppressing osteoblast differentiation. T2DM is regarded as a disease of slow turnover
(Purnamasari et al., 2017). In addition, the results also show that it suppresses
osteoblast differentiation and at late stages of diabetes (10,14 weeks ) also suppresses
osteoclast activity. Moreover, miR-21 and miR-155 could be used as potential serum
biomarkers. The study also suggests, the longer duration of T2DM affects adversely
the bone microstructure, indicating an increased bone fragility.
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5.1 Future Work
Many clinical studies have shown an increased cases of fracture or bone
injuries in type 2 diabetic patients. This suggests a close relation between type 2
diabetes and osteopathies such as osteoporosis. Another group of researchers have
shown certain alteration in the microRNAs expression in case of osteoporetic animal
models. Therefore, in this study the interest was in finding the expression of those
microRNAs which were seen to be altered in osteoporetic animal models. Hence, the
expression of microRNAs were determined in type 2 diabetic rats. It’s been found that
certain miRNAs to be diferrentially expressed in type 2 diabetics rats. These
microRNAs target the key regulators of bone remodeling cycle. This gives an insight
for the possible relation between type 2 diabetes and osteoporosis. For future studies,
it would be fascinating to decode the possible association between type 2 diabetes and
osteoporosis. It would be interesting to analyze the expression of the differentially
dysregulated miroRNAs from this current study in the osteoporetic rat models.
Furthermore, the effect of microRNAs can be studied further on protein level using
western blotting and immunohistochemistry. This will give a functional understanding
of each microRNAs and target genes. Addiotionally, analyzing the levels of bone
resorption markers in order to understand the modulation of bone remodeling cycle is
crucial to be further studied.
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Appendix

8 weeks - Control
Animal Assigned No.

Weight (g)

Blood Glucose Level

Animal #6

328.5

109

Animal #7

217.5

114

Animal #8

247.5

113

8 weeks – T2DM
Animal Assigned No.

Weight (g)

Blood Glucose Level

Animal #23

435

435

Animal #24

308.5

558

Animal #25

262.5

428

10 weeks - Control
Animal Assigned No.

Weight (g)

Blood Glucose Level

Animal #9

263

127

Animal #10

209

107

Animal #11

230

113

10 weeks – T2DM
Animal Assigned No.

Weight (g)

Blood Glucose Level

Animal #12

172

458

Animal #13

224

499

Animal #14

228

447

122
14 weeks - Control
Animal Assigned No.

Weight (g)

Blood Glucose Level

Animal #1

250

119

Animal #2

220

131

Animal #16

252

117

14 weeks – T2DM
Animal Assigned No.

Weight (g)

Blood Glucose Level

Animal #13

235

123

Animal #15

187

457

Animal #23

282.5

493
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